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ABSTRACT OF THE DISSERTATION 
DETERMINANTS AND DISPARITIES OF SURVIVAL IN TRIPLE-NEGATIVE 
BREAST CANCER PATIENTS: A POPULATION-BASED RETROSPECTIVE 
LONGITUDINAL COHORT STUDY DESIGN UTILIZING THE COX 
PROPORTIONAL HAZARD ANALYTICAL MODEL 
by 
Michael C. Belcon 
Florida International University, 2015 
Miami, Florida 
Professor Nasar U. Ahmed, Major Professor 
A significant racial disparity in breast cancer mortality exists among women in the 
United States. Triple-negative breast cancer (TNBC) is a breast cancer phenotype that 
may explain, in part, this disparity between white and African American women. The 
objective of this study was to determine the predictors of survival in TNBC and non-
triple-negative breast cancer (NTNBC) patients.  
Data on 168,756 female patients with a diagnosis of invasive breast cancer in the 
Surveillance Epidemiology and End Results (SEER) program were stratified based on 
breast cancer receptor phenotypes in this retrospective longitudinal cohort study design. 
Multiple logistic regressions were used for exploring predictors of treatment which 
showed that not receiving surgery as standard treatment was associated (odds ratio: 95% 
CI) with TNBC (OR 1.151: 1.042, 1.177), uninsured (OR 3.552: 3.206, 3.937) and 
African American (OR 1.804: 1.702, 1.912) while not receiving radiation was associated 
with TNBC (OR 1.151: 1.113, 1.190), uninsured (OR 1.318; 1.217, 1.429). Cox’s hazard 
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models were used, regressing age, race, ethnicity, marital status, health insurance status, 
histological tumor grade, and treatment status on survival time, the outcome measure.  
Analysis revealed that the mean survival time is lower for TNBC [15.60 (± 
10.29)] months compared with NTNBC [16.01 (± 10.18)] (p < 0.0001), a difference 
though small is statistically significant. The independent determinants of survival in 
TNBC were: young age at diagnosis [(β = 0.033, HR 1.033 (1.026, 1.041)]; being African 
American [(β = 0.182, HR 1.200 (1.117, 1.289)], being married [(β = - 0.362, HR 0.697 
(0.658, 0.737)]; higher tumor histological grades [β = 1.034, HR 2.812 (2.159,3.661)];  
uninsured [(β = 0.541, HR 1.717 (1.481, 1.992)]; no surgery [(β = 2.156, HR 8.633 
(8.152, 9.143)], or no radiation treatment [(β = 0.489, HR 1.630 (1.535,1.73)]. 
African American race, uninsured status, higher grade at diagnosis, inadequate 
treatment are independent predictors of poor survival among breast cancer patients; 
importantly, TNBC had a lower survival than that of NTNBC patients. A higher 
proportion of TNBC patients had a diagnosis at younger age, with higher tumor grade 
and was of the African American race. The survival disparity in African American 
patients may be partially explained by disproportionately higher TNBC cases among 
them, as well as, rates of not receiving standard treatments.  
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DEFINITIONS 
 
Adjuvant therapy  
This is used for prophylaxis against potential recurrence or spread and after surgery and 
includes (1) radiation therapy to regional lymph nodes and to chest wall after modified 
radical mastectomy, (2) Systemic therapy with endocrine agents for ER+, PR+, 
chemotherapy, and monoclonal antibodies especially for HER2+ breast cancer and can be 
combined with chemotherapy.  
 
Targeted neoadjuvant therapy 
Treatment administered to shrink tumor size after needle biopsy but before other surgery 
of any kind 
 
Race and Ethnicity 
The definition of race and ethnicity used in this undertaking is based on the US Office of 
Management and Budget’s definition of race and ethnicity contained in the Federal 
Register Notice, October 30, 1997 and operationalized in the US Census Bureau 
publication “Race” revised July 8, 2013. The terms African American and Black are used 
interchangeable, especially as used in cited studies. In this same classification ethnicity is 
defined as Hispanic/Latino and non-Hispanic/non-Latino.  
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CHAPTER I 
 
INTRODUCTION 
 
i. Background 
 
After skin cancer, breast cancer is the most common form of cancer amongst women in 
the United States (CDC, 2009) and the second leading cause of cancer death in women 
after lung cancer (SEER Cancer Statistics Factsheets: Breast Cancer, 2015). In general, 
white women have a higher incidence and lower mortality rate that African American 
women with breast cancer (American Cancer Society (ACS). Cancer Facts and Figures. 
2013-2014)). However, for women younger than 45 years the incidence of breast cancer 
is higher in African American women than white women (NAACCR, 2011; Howlader, et 
al., 2011). Compared with white women, the mortality rate among African American 
women is not only higher for younger age groups but is higher for all age groups 
(American Cancer Society (ACS). Cancer Facts and Figures. 2013-2014). Recently, the 
discovery that triple-negative breast cancer also may have a significantly higher mortality 
in African American, raises the possibility that this subset of breast cancer may partly 
explain the persistent disparity in breast cancer mortality. 
   
ii. Conceptual Framework 
 
The conceptual framework of this study is based on the Harvard TREC model of 
multilevel interactions of factors that influence cancer risks and predictors of survival 
(Harvard Transdisciplinary Research in Energetics and Cancer Center). These factors 
include genetic, behavioral, structural, sociological and biological factors that are 
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interrelated and linked to the development of cancer and its outcome. The framework 
encompasses disparities among these factors that alter the differential potential for 
development of cancer (Kilboume et al., 2006). Once cancer develops there are other 
factors including socioeconomic correlates that influence cancer pathophysiology, health 
care access, and response to treatment that influences survival. The present study 
envisioned this model to link predictive factors such as age, race, marital status, tumor 
grade, tumor stage, health insurance availability and treatment provided, all of which in 
turn affect prognosis and ultimately the outcome of survival (Figure 1). 
 
 
                   Figure 1: Conceptual framework for breast cancer survival study. 
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iii. Problem Statement 
African American women have higher mortality from breast cancer than white women do 
and recent evidence suggests that one subset of breast cancer, TNBC, may be so lethal as 
to partially explain this higher mortality. Therefore, to better understand these 
observations, there is a need to better estimate: (a) the magnitude of survival in TNBC 
compared to NTNBC patients in the population, (b) the racial disparity in survival among 
TNBC patients, and (c) the predictors of survival among TNBC and NTNBC patients.  
 
iv. Research Questions 
 
 
Research Question 1: Is survival lower in TNBC patients compared to NTNBC patients? 
 
Research Question 2: Are there racial/ethnic disparities in survival in TNBC patients? 
Research Question 3: Are there clinical and sociodemographic variables that predict 
survival among TNBC and NTNBC patients? 
 
v. Study Rationale 
 
 
African American women have the highest mortality rate among all racial and ethnic 
groups. TNBC is a very lethal subset of breast cancer. Smaller population studies have 
suggested that mortality differences among racial groups do exist among TNBC patients, 
but no large scale population study has examined survival differences between racial and 
ethnic groups among TNBC patients using survival analysis statistical methods (Boyle, 
2012). Could lower TNBC survival explain the higher mortality seen in overall breast 
cancer? If so, what are the variables that explain this poorer survival?  
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Although the Carolina Breast Cancer study explored survival differences among 
basal-like, liminal A and luminal B breast cancer subsets (Carey et al, 2006), no large-
scale population study has yet evaluated survival among TNBC and NTNBC patients 
using survival analysis statistical methods (Boyle, 2012).                 
The ultimate rationale of this study then is to better estimate and define some of the 
epidemiological factors that may predict the high mortality and low survival of TNBC in 
certain racial and ethnic groups in the population from a large population database.  
No large scale study has yet explored the epidemiological determinants that define the 
differences of TNBC and NTNBC patients using Cox proportional hazard methods of 
statistical analysis (Boyle, 2012).         
It is the purpose of this study to provide data on these unanswered questions. 
Furthermore, the epidemiology of TNBC compared to NTNBC is still not well-defined 
currently. In fact, the burden of TNBC is only now being explored in the literature and 
needs to be better understood. It is one of the prerogatives of this study to better define 
the relative prevalence of TNBC in these population subsets and the factors contributing 
to TNBC survival. In the end, the purpose of this study is to evaluate which clinical and 
socioeconomic determinants have the biggest impact on TNBC survival.  
 
vi. Specific Aims 
 
 
The long term goal of this study is to close the existing epidemiologic information gaps 
in breast cancer, specifically between TNBC and NTNBC patients. The study can achieve 
this by providing a better understanding of the existing survival disparity and by 
identifying the possible predictors of survival among TNBC. In the broader context, the 
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study’s goal is for the study results to form the basis of effective public health programs 
and policies that would narrow the disparities that exist among minorities with breast 
cancer. 
 
Specific Aim 1: The main aim of this study is to evaluate survival differences between 
racial and ethnic groups among TNBC patients from a large national database.  
Hypothesis 1: Survival is lower in African American patients compared with Non-
Hispanic white women.   
Specific Aim 2: To compare the survival between TNBC and NTNBC so as to determine 
if survival is lower in TNBC compared to NTNBC patients.  
Hypothesis 2: Survival is lower in TNBC patients compared with survival in 
NTNBC patients.  
Specific Aim 3: To examine if treatment, clinical and sociodemographic factors predict 
survival in both TNBC and NTNBC patients.  
Hypothesis 3: Treatment, clinical and sociodemographic characteristics predict 
survival in TNBC and NTNBC patients. 
 
vii. Potential Contribution to Current Body of Knowledge 
 
Since TNBC has such a poor prognosis, knowledge of the impact of this breast cancer 
subset on the overall mortality of breast cancer may have a significant impact on the 
overall knowledge of breast cancer survival in the general population. While awareness 
of factors affecting survival among breast cancer patients appears to be better understood 
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in the general population, why TNBC is disproportionately lethal compared to NTNBC 
patients especially in the minority population, is not well understood. What are the 
factors contributing to survival in TNBC patients? What is the prevalence of TNBC 
among minority populations estimated from larger population databases? What other 
epidemiological factors distinguish TNBC from NTNBC and how significant are they as 
contributors to survival? Answering some of these questions can add substantial 
information to our current body of knowledge. The need for answers and results that this 
study can provide is compelling. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
 
The conceptual framework of this study encompasses behavioral, structural, biological 
and socioeconomic constructs that influence not only the risk factors for development of 
breast cancer but also the predictors of survival following the development of breast 
cancer (Kilbourne et al, 2006). These factors are not well delineated for TNBC and other 
breast cancer subsets and there remains significant gaps in available knowledge about the 
epidemiology of this disease and its subsets.  
The overarching objective of this study is to address the epidemiologic 
information gaps among TNBC and NTNBC patients and the factors influencing survival 
in this population. An understanding of breast cancer is therefore essential in this process. 
In that direction, it is important to first understand that there is significant heterogeneity 
among breast cancers, each with unique therapeutic and prognostic implications 
(Goldhirsh et al., 2011; Esposito, Criscitiello, & Curigliano, 2015). Up to 27% of all 
breast cancers in some studies are considered triple-negative (Carey et al., 2006; Dawson, 
Provenzano, & Caldas, 2009; Morris et al., 2007; Kaplan, & Malmgren JA, 2008). Triple-
negative breast cancer (TNBC) is a phenotype which is clinically negative for expression 
of the estrogen and progesterone receptors (ER and PR) and lacks overexpression of the 
HER2/neu protein (Boyle P, 2012). (Note: HER2/neu has been referred to as HER2 or 
human epidermal receptor type 2 and more recently, erb-b2 tyrosine kinase2 and v-erb-b2 
avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2). HER2 will be used in 
this discourse to denote the same entity).  
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On an immunohistochemical level, TNBC shares salient features with basal-like breast 
cancer with which it is often confused but there is up to 30% discordance between the 
two (Nielsen et al., 2004; Kreike et al., 2007; Bertucci, et al., 2008; Cleator, Heller, & 
Coombes, 2007). So the distinction should be made that the term TNBC refers to the 
immunohistochemical classification of breast cancers lacking ER, PR, and HER2 protein 
over expression, a phenotypic manifestation of genetic expression, while the basal-like 
subtype is defined by gene expression microarray analysis. 
Clinically, TNBC differs from other subtypes of breast cancers in its predilection to 
younger women especially those who are African American and carries significantly 
different therapeutic and prognostic implications. A pattern is developing about TNBC 
from the smaller population studies currently available, one aspect of which is that 
women with TNBC tend to be disproportionally premenopausal and African American.  
TNBC carries a worst prognosis than other subsets of breast cancer (Rastelli & 
Crispino, et al., 2008). In this group, the disease tends to be diagnosed at a more 
advanced stage, with more lymph node involvement, larger tumor size, higher tumor 
grade and with more mitotic activity and cell growth fraction as measured by Ki-67 
nuclear protein index; TNBC metastasizes earlier and to distant organs, especially 
visceral organs, as well as brain metastasis. Women with TNBC also tend to have earlier 
breast cancer recurrence, within 3 years of treatment. Reliance on common forms of 
treatment for TNBC has been relatively ineffective. This is especially so for hormonal 
manipulation including selective estrogen receptor modulators (SERM) and aromatase 
inhibitors and to a lesser extent radiotherapy and currently available biological therapy 
(Langland, Horgan, Dodwell & Smith, 2013).  
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Breast conserving surgery and chemotherapy have been the mainstay of treatment, thus 
far. The efficacy of biological therapy in TNBC is still uncertain but is currently in 
clinical trials (Tinoco, Warsch, Glück, Avancha, & Montero, 2013). Because of poor 
responses to standard therapeutic interventions there has been a recent focus on more 
novel forms of treatment for TNBC including EGF receptor, alpha B crytallin, PARP 
inhibitors and Cyclin E therapeutic approaches (Crown, Oshaughnessy, & Gullo, 2012; 
Malin et al., 2013). A consensus is developing that TNBC is a breast cancer subset with 
unique clinical, therapeutic and prognostic challenges compared to other subsets.    
 
Figure 2: Top ten cancer sites 2012: male and female, United States – all races. 
 
Taken from: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 Incidence 
and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention and National Cancer Institute; 2015. Available at: www.cdc.gov/uscs. 
 
Despite this, little is known about the epidemiology of TNBC from large scale population 
studies. The incidence, prevalence, mortality rate, mean age at diagnosis, racial and 
ethnicity profile for TNBC has been inferred from smaller population studies. Many of 
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the factors affecting survival in TNBC are still to be better delineated. It is the purpose of 
this dissertation to better clarify some of the factors affecting survival of TNBC patients 
utilizing the large national database in the Surveillance, Epidemiology and End Results 
(SEER) program and Cox proportional hazard analytic model (Cox DR, 1972).    
TNBC is but one subset of breast cancer and an overview of the entirety of breast cancer 
as a whole is essential to place the TNBC subset in its broader perspective. Much is 
known of breast cancer as a whole, while TNBC is only now being elucidated. In 
addition, much of what is known about the epidemiology of TNBC is based on the 
proportion of epidemiological indices of breast cancer overall as it relates to its subsets. 
Therefore, knowledge of breast cancer epidemiology is important to fully understand the 
epidemiology of TNBC.  
 
i. Breast Cancer Epidemiology 
 
Since the goal of this study is to address the existing epidemiologic information gaps in 
breast cancer, specifically between TNBC and NTNBC patients, clearly, an overview of 
what is known, or unknown about breast cancer epidemiology provides an essential 
perspective to better understand the intricacies of its subsets, TNBC and NTNBC.  
After skin cancer, breast cancer is the most common cancer amongst both men 
and women in the United States (CDC. Breast Cancer Rates by Race and Ethnicity 1999 
– 2011, 2014).  Figure 1 is from data published in 2015 which excludes skin cancer, and 
shows breast cancer as having the highest incidence among 10 of the most common 
cancers in the population. Thirty two percent of all cancer cases diagnosed in women are 
due to breast cancer (American Cancer Society, 2012).  
11 
 
 Table 1: Age-specific breast cancer incidence rates per 100,000 (2008-2012). 
Age at Diagnosis Non-Hispanic White Black 
20-24 1.3 2.0 
25-29 8.5 11.8 
5.139-34 26.6 34.3 
35-39 59.4 68.2 
40-44 122.0 123.4 
45-49 191.8 183.5 
50-54 227.2 225.4 
55-59 268.8 278.2 
60-64 353.6 341.6 
65-69 437.9 397.8 
70-74 460.1 422.8 
75-79 469.9 420.8 
80-84 438.2 408.1 
85+ 362.1 364.0 
From: 
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, 
Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 
1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on 
November 2014 SEER data submission, posted to the SEER web site, April 2015. 
 
Table 1 shows data from 2008 – 2012, where the breast cancer age-adjusted 
incidence is 122.2 per 100,000 adjusted to the 2000 U.S. standard. It is estimated in 2015 
that 231,840 women in the US will be diagnosed with breast cancer and 40,290 women 
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will die from the disease in that same year (SEER Cancer Statistics Factsheets: Breast 
Cancer, 2015).  Based on 2008 - 2012 data, the lifetime probability of a US woman 
developing breast cancer is 1:8. Put another way, 12.3 % of women in the United States 
will be diagnosed with breast cancer in their lifetime, the highest among all cancers by 
site (Howlader et al., 2012).  
The overall age-adjusted annual incidence of breast cancer from 2008 - 2012 is 
124.8 per 100,000, slightly higher among whites (128.3 per 100,000) compared to 
African-Americans (124.3 per 100,000).  
Before age 45 years, African-American women have a higher incidence of breast 
cancer compared to non-Hispanic whites, but after age 45 there is a crossover of 
incidence in which the incidence of overall breast cancer is higher in non-Hispanic white 
women compared to African-American women (NAACCR, 2011, Howlader, et al., 
2011). This data is tabulated in Table 1. 
Until quite recently, trends indicated that breast cancer incidence increased over 
the past four decades. Between 1999 and 2009 the incidence decreased by 2% per year 
but most of that incidence decrease occurred in women age 50 and older. Before that, the 
rate of increase was most rapid in the 1980s, mainly as a result of increased early 
detection through mammography. By year 1999, the incidence started to decrease 
particularly among women 50 years and older (ACS - American Cancer Society, 2010). 
In addition to a decrease in actual breast cancer cases detected, this recent decrease in 
incidence may also be due to a low adherence to mammography screening  (Clarke et al., 
2013), although a decreased use of hormonal replacement therapy a decade before may 
have been a contributing factor (Zbuk & Anand, 2012).  
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The prevalence of breast cancer in 2012 is estimated at 2,975,314 indicating a significant 
burden of breast cancer in the US population. The risk of developing breast cancer 
increases with age with the 10-year risk put at 1 in 71 for a woman at age 40 years, 1 in 
42 at age 50 years, and 1 in 29 at age 60 years (Altekruse et al,. 2010). This can be stated 
another way. Data from 2008-2012 show the percentage of women diagnosed with breast 
cancer increases from 0% in those under age 20 years to 25.6% in those 55 – 64 years 
(See Table 2). The peak incidence occurs in the 55 – 64 age-group. But the incidence of 
breast cancer between ages 35 – 44 years is not trivial, with 10.9% of all cases occurring 
before age 45 years and fully 32.5% or 1/3 of all cancer cases occurring before the peak 
incidence age group (Howlader et al., 2014). 
Despite the passage of time, the disease is still very lethal among US women. 
After lung cancer (26.8% of cancer deaths), breast cancer is still the second leading cause 
of death among US women accounting for 6.8% of all cancer deaths (CDC NCHS, 2014. 
From 2005 – 2011 data, the five-year survival rate for breast cancer is 89.4%, worst for 
distant metastasis (Stage IV) at the time of diagnosis at, 25.9% (SEER Cancer Statistics 
Factsheets: Breast Cancer, 2014). From the same data, it is estimated that 40,290 women 
will die from breast cancer in the year 2015. 
Between 2008 and 2012, the overall age-adjusted mortality rate of breast cancer 
was 21.9 per 100,000 with 32.4 per 100,000 in African-Americans compared to 23.9 per 
100,000 among White women (SEER Cancer Statistics Factsheets: Breast Cancer, 2015). 
While two of the leading causes of death - heart disease and stroke - have had a 
substantially decreased mortality (60% decrease) between 1950 and 2005, cancer 
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mortality has decreased only slightly (5%) from 193.9 to 183.8 per 100,000 during those 
years (NCHS, 2009) and the burden is particularly weighty for the minority populations. 
 
Table 2: Percentage of women diagnosed/died from breast cancer by age groups.  
Age (years) Percentage Diagnosed Percentage who died 
< 29 0.0 0.0 
20 - 34 1.8 0.9 
35 - 44 9.1 5.1 
45 - 54 21.6 14.3 
55 – 64 25.6 21.9 
65 – 74 21.9 21.0 
75 – 84 14.2 20.5 
>84 5.7 16.4 
Data from 2008- 2012. From: Howlader, et al., 2014 
 
 
Epidemiology of Breast Cancer in US Racial and Ethnic Minority Populations: In the 
period 2008 -2012, the age-adjusted incidence of breast cancer was 124.8 per 100,000. 
For African Americans it was 124.4 per 100,000, White 127.9 per 100,000, Asian/Pacific 
Islanders 96.3 per 100,000, American/Alaska natives 82.0 per 100,000. For Hispanics it 
was 92.1 per 100,000 and Non-Hispanics 130.1 per 100,000. African Americans have a 
33% higher risk of dying from cancer than Whites (Ries L, et al., 2006) and about 2.8 
times as much mortality risk compared to Asian American/Pacific Island (AA/PI) women 
(34.6 versus 12.3 per 100,000) (Stewart et al., 2004).  
Between 2008 -2012, there was a racial gradient in female breast cancer death 
rates with the highest among African American women (30.2 per 100,000), followed by 
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White, American Indian/Alaska natives, Hispanics and Asian American/Pacific Island 
women (21.3, 15.0, 14.5 and 11.4 per 100,000 respectively). Age-adjusted to 2000 US 
standard population, the breast cancer mortality rate in 2000 among African Americans 
was 33.8 compared to 25.0 per 100,000 in 2009.  
 
Figure 3: Age-specific breast cancer incidence and mortality rates.  
 
Age Disparity in Breast Cancer Incidence: In women, the incidence of breast cancer 
increases with age and doubles every 10 years until menopause when the rate of increase 
slows. Approximately 25% of breast cancers affect women under the age of 50 years, 
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with 50% occurring between the ages of 50 and 69 years and the remaining 25% 
developing in women who are 70 years or older.  
The trend of change in incidence and mortality with age, although similar for both 
races, shows that breast cancer tends to occur at a younger age in African Americans with 
separation of, and higher mortality rates between, the races in all age groups. The average 
age of breast cancer diagnosis in African American women is 46 years, compared to 57 
years for white women (CDC, 2010; (Retsky et al., 2005; Howlader et al., 2012).  
Disparity in Lethality: Figure 2 shows the breast cancer incidence and mortality rates by 
age among Non-Hispanic whites and African American women. Recent research suggests 
that in African American women breast cancer appears to be more aggressive and lethal 
than in White women. Analysis of data from the Women’s Health Initiative Study 
revealed that African American women had more high-grade and estrogen receptor 
negative tumors, at a rate five times as much as White women. Both findings together 
indicate that these aggressive breast cancers are more difficult to treat and are associated 
with poorer outcomes (Chlebowski et al., 2003; Li et al., 2002; Miller et al., 2002).  
These same studies also confirmed that African American women are more likely 
to be diagnosed with late-stage disease than white women are (45 percent compared with 
33 percent) (Leserman et al., 1993). This observation was also demonstrated with other 
ethnic minority groups. In one study by Lantz et al. (2000), African American and 
Hispanic women were less likely to be diagnosed with early-stage breast cancer than were 
White women (P < 0 .001). After controlling for study site, age, and individual 
socioeconomic factors, the odds of early detection were still significantly less for 
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Hispanic women (odds ratio [OR] = 0.45, 95% CI = 0.31 – 0.64) and African Americans 
women (OR = 0.72, 95% CI = 0.54 – 0.96) than for White women (Lantz et al., 2000). 
 
ii. Breast Cancer Risk Factors  
                                      Table 3: Risk factors for breast cancer. 
FACTOR FACTOR DETAIL 
Relative 
Risk 
Age Over age 50 > 4.0 
Gender Female > Males > 4.0 
Family history Breast cancer in first-degree relatives, particularly if 
BRCA1 or BRCA2 
> 4.0 
Personal history Previous breast cancer in ipsilateral or contralateral 
breast 
> 4.0 
Hormonal 
Influence 
Long menstrual history: early menarche and late 
menopause  
Menstrual  
1.1 – 2.0 
Parity Nulliparous or first full-term pregnancy at age 40 or 
older.  
Postmenopausal hormone therapy use  
> 4.0 
Breast feeding Not having breastfed or having breastfed for less than 
12 months (i.e., total for all births)  
 
> 4.0 
Obesity Particularly post-menopausal obesity. Overweight 
women were 60% more likely to die from breast 
cancer than were normal-weight women (Calle, 
Rodriguez, Walker-Thurmond & Thun, 2003); a 
higher risk of breast cancer has been associated with 
weight gain after menopause (Lahmann, Lissner, 
Gullberg, Olsson, & Berglund, 2003);  
> 4.0 
Environmental 
exposure 
Moderate to heavy alcohol intake (i.e., > 1 drink/day), 
estrogens, chest radiation 
2.1 – 4.0 
Previous breast 
biopsy 
Abnormal breast biopsy 2.1 – 4.0 
 Adapted from: Hulka & Moorman, 200 
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To best appreciate factors predicating survival is to understand the known risk factors for 
developing breast cancer. The number one risk factor for developing breast cancer is 
female gender (ACS, 2011). Breast cancer is gender specific. The disease has an 
overwhelming predilection for women. While it does occur in men, almost all cases occur 
in women. Consistent epidemiological data has repeatedly shown that about 99.5% of 
people developing breast cancer are female and less than 0.5% are male (ACS, 2011).  
Besides sex, generally, the risk factors for breast cancer are based on several other 
factors including age, familial or genetic factors, environmental, endocrinological and 
host factors (such as breast density and proliferative breast disorders) (Table 3). 
 
Age and Race: The life time risk of a woman developing breast cancer is about 1:8 or 
12.5%. By decades, the 10 year risk increases to about 25% in the 4th decade and 35% in 
the 5th decade of life (SEER, 2011).  Age is the single most important risk factor for the 
development of breast cancer. Table 4 shows the percentage risk of developing breast 
cancer for various age groups in the year 2000. 
This percentage risk increases with age and is highest after age 80 years old. Table 
5 shows the incidence of breast cancer as a function of age for various racial and ethnic 
groups. The average age of breast cancer diagnosis in African American women is 46, 
compared to 57 years for Whites (Retsky et al., 2005; Howlader, et al., 2012). 
For the general population the incidence of breast cancer increases from age 40 to 
over age 70 and after which it levels off. For African Americans the breast cancer 
incidence is higher than Whites between age 40 and age 50 years. After age 50 years the 
incidence is higher in Whites than African Americans. 
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                     Table 4: Breast cancer risk by age in all US women – 2000. 
Age Group 
(Years) 
Breast Cancer Risk 
(%) 
< 30 0.004 
30 – 39 0.43 
40 – 49 1.44 
50 – 59 2.65 
60 – 69 3.65 
70 – 79 4.73 
> 80 14.3 
After: Ries et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute, 
2006. 
 
This crossover in incidence between white women and African American women with 
breast cancer as a function of age-groups has not been observed in comparisons with 
other racial and ethnic groups (Figure 3).  
 
Table 5: Incidence of breast cancer in the population – 2012* 
Age 
Group 
All 
Races 
White Black Asian/Pacific 
Islander 
American 
Indian/Alaska 
Native 
Hispanic 
25 -29 9.1 8.4 12.4 8.2 - 6.0 
30-34 27.4 26.2 32.8 23.9 13.4 20.2 
35-30 60.1 59.1 66.1 51.5 33.1 45.9 
40-44 121.3 121.0 126.0 106.7 49.4 91.1 
45-49 184.5 185.1 180.2 169.8 84.6 138.8 
50-54 219.4 219.3 225.1 184.5 129.0 169.6 
55-59 254.6 254.6 266.4 203.0 122.7 201.3 
60-64 327.8 331.1 328.5 289.9 239.4 308.7 
65-69 418.1 426.1 385.8 289.9 239.4 321.9 
70-74 440.1 451.2 398.4 264.2 289.4 308.7 
75-79 442.6 454.5 400.9 234.2 273.6 310.4 
80-84 407.3 414.9 369.5 229.1 290.2 278.4 
85+ 332.9 333.7 329.0 182.5 147.9 244.5 
                          
 *(Incidence per 100,000 by Age, Race and Hispanic Ethnicity, 2012). 
Taken from: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 Incidence 
and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention and National Cancer Institute; 2015. Available at: www.cdc.gov/uscs.  
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Interestingly, age-adjusted mortality rates for breast cancer are higher in African 
American than whites for all age-groups.  
Familial Considerations: First degree relatives (mother, siblings, etc.) of index breast 
cancer cases are at highest risk for getting breast cancer independent of known genetic 
factors. Second degree relatives (aunts, grandmothers, cousins) are at a lower risk. 
   
        Figure 4. Breast cancer age-adjusted mortality rates by race/ethnicity 2000 - 2012. 
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Genetic Factors: To some extent the familial risk of developing breast cancer is related to 
the mode of gene inheritance, known or unknown. A number of such breast cancer genes 
(oncogenes) have been identified including BRAC1, BRCA2, erb-B2, p53, c-myc, cyclin 
D-1, and CDK-1, the presence of which may convey increased risk of developing breast 
cancer. Mutations of BRCA 1 and 2 suppressor genes are the more commonly known of 
these which are frequently tested among women at risk in the population and have been 
shown to be inherited in an autosomal dominant fashion (King et al., 2003). 
 
Environmental Factors: A number of putative environmental factors have been found to 
be related to breast cancer development. High among these is ethanol intake which has 
been shown consistently in controlled, as well as in pooled and meta-analytic studies 
(Longnecker, 1994; Smith-Warner et al., 1998; Key et al., 2006; Tjonneland et al., 2003). 
Alcohol consumption and breast cancer has been fairly well researched. Earlier studies 
have had methodological issues that made firm conclusions regarding the association 
difficult, but later studies, as well as, pooled and meta-analytic studies consistently 
showed a risk-association which is dose-dependent and independent of beverage type.  
In a more recent review of a large number of studies, alcohol consumption of up 
to 24 grams (2 drinks) per day increases the risk of developing breast cancer by 21% 
(McDonald J, Goyal A & Terry MB, 2013). Risk assessment modeling shows a stratified 
risk for developing breast cancer which depends on the quantity of chronic alcohol 
ingestion in both animals and humans (Boyle & Boffetta, 2009; Key et al., 2006). Other 
putative environmental risk factors for breast cancer include exposure in utero to the 
pesticide DDT (Cohn et al., 2015), which needs further studies for confirmation. 
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Endocrinological Factors: Early menarche before age 12, late menopause after age 55, 
late or no pregnancy and limited breast feeding have been cited as risk factors for 
developing breast cancer. Delayed childbearing, low fertility and decreased physical 
activity may also increase the risk of breast cancer (ACS, 2004). Among Black women 
parity may have a dual effect on breast cancer risk (Palmer, et al., 2003).  
Avoidance of combination hormonal replacement therapy appears to be a prudent 
way to reduce cancer risk at this time based on current data. Based on an analysis of 
current data the US Preventative Service Task Force has recommended that combination 
HRT (estrogen and progestins) be avoided among post-menopausal women for routine 
prevention of chronic disease (Moyer et al., 2012). Interestingly women who use SERMs 
may be at a lower risk of developing breast cancer but the evidence is preliminary and 
inconclusive such that definitive recommendations cannot be made at this time 
(Cummings et al., 2009).   
While routine use of tamoxifen cannot be advocated as a primary prevention 
measure, there is good evidence that among high risk individuals from an ongoing US 
follow up study, this agent reduced the risk of breast cancer by 49% (Vogel, 2001). In 
another multicenter international study, the risk reduction seen in the group taking this 
drug was 32% compared to placebo (Cruzik et al., 2007). Adverse effects with the drug 
may preclude routine use among women. The risk of endometrial cancer appears to be 
higher among women on long-term tamoxifen therapy (Curtis et al., 1996). However, in 
postmenopausal women who have had a hysterectomy and are high risk for breast cancer 
chemoprophylaxis with tamoxifen may be a consideration (Cuzick et al., 2014). Table 6 
provides an interpretation of the various determinants of breast cancer. 
23 
 
                        Table 6: Determinants of breast cancer development. 
 
General Risks Specific Risk Factors Interpretation 
Age 40 – 49 years – 20% 
50 – 59 – 30% 
60 – 70 – 35% 
Increases with age in all subgroups 
Race Whites ( > 40 years) 
Blacks ( < 40 years) 
After age 40 years whites at higher 
risk 
Family History First degree 
(Mother, Sister) 
Second degree relatives (aunts, 
grandmothers, cousins, etc.) 
Genetic BRCA I and II Genes 5% Cases overall 
Host Factors Dense breast (Mammography) 
 
 
 
 
 
 
 
Obesity 
Histological correlates    
a. Fibroadenoma with complex 
features, 
b. Hyperplasia without atypia  
c. Sclerosing adenomas  
d. Solitary papillomas 
e. Atypical Hyperplasia, (lobular 
and ductal)  
f. Lobular carcinoma in situ 
Truncal Obesity 
Environmental Hormonal exposure Oral contraceptives and hormonal 
replacement 
 
Early menarche before age 12 
Late menopause after age 55  
 Carcinogens Alcohol, excessive radiation 
exposure 
Previous 
Cancers 
Breast cancer in one breast Gynecological cancer, ovary, 
cervix, endometrial 
Colon Cancer 
 
Host factors: A number of host factors have been implicated in breast cancer risk 
association (Goodwin, 2008; McPherson, Steel & Dixon, 2000). This is especially so for 
radiological and histological abnormalities that has been cited as identifiable risk factors 
for breast cancer (Amir, Freedman, Seruga & Evans, 2010). These include dense breast 
tissue on mammography and histological features on pathologic examination of breast 
tissue including fibroadenoma with complex features, hyperplasia without atypia, 
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sclerosing adenomas, solitary papillomas, atypical lobular and ductal hyperplasia and 
lobular carcinoma in situ (Guray, 2006). Obesity, especially truncal redistribution of fat, 
is putative causation factor for breast cancer (Morimoto et al., 2002) and has been 
suggested to be a significant risk factor for TNBC as well, in a comprehensive and 
detailed evaluation by Pierobon & Frankenfeld, in a meta-analytical study (Pierobon & 
Frankenfeld, 2013) as well as, other smaller but representative studies. 
Previous Cancers: Previous occurrence of breast cancer in one breast is an extremely 
high risk factor for the development of breast cancer in the same or the other breast 
(Chen, Thompson, Semenciw, & Mao, 1999). The development of colon and some 
gynecological cancers such as ovarian, cervical and endometrial cancers is a known risk 
for the development of breast cancer (McPherson, Steel, & Dixon JM, 2000), particularly 
in hereditary conditions like Lynch syndrome (Lynch, Lynch, Lanspa, & Snyder, 2009).  
For asymptomatic individuals in the population, these same determinants for cancer 
development can be stratified by degree of risk a priori in the general population.  
This type of classification may then have implications for screening with specific 
measures such as mammography and MRI. But more importantly, this initial step can 
also have implications for assessment of prognosis before proceeding to the next step, 
establishing the diagnosis with measures such as ultrasonography and ultrasound guided 
biopsy. Perhaps the greatest benefit arising directly from and assessment of risk and risk 
stratification is the altering of modifiable risks by the institution of primary or secondary 
prevention measures which have a better likelihood of altering the course of the disease 
process. Table 7 is a display of breast cancer stratification into different levels of risk 
namely: moderate risk, slightly higher risk and highest risk. 
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                Table 7: Stratification of breast cancer risk-factors by degree of risk. 
 
Highest Risk Moderate Risk Slightly Lower Risk 
Breast cancer      
in one breast 
Age -  50 – 59 
           40 – 49 
           60 – 70 
Family history – second degree relatives 
(aunts, grandmothers, cousins 
 Family history 
    First degree 
Histological lesions – Fibroadenoma with 
complex features, hyperplasia without 
atypia, Sclerosing adenomas, solitary 
papillomas. 
Dense breast on mammogram 
 Genetic trait  
    BRCA 1, 2 
Early menarche before age 12 
Late menopause after age 55 
 Breast Lesions 
   Atypical hyperplasia  
   Lobular carcinoma in    
   situ 
Overweight or obese especially truncal 
  Excessive radiation – following disease 
treatment 
  Family history of colon cancer, or 
gynecological cancer ( ovary, cervix, 
endometrial) 
  Race – whites, blacks under age 40 
  Chemicals – alcohol, oral contraceptive 
and hormonal replacement therapy 
 
 
iii. Breast Cancer Receptor Biology and Phenotypes 
 
 
The main aim of this study is to evaluate survival in breast cancer phenotypes. An 
understanding of the receptors that distinguish these phenotypes is therefore essential and 
the biological behavior of breast cancer receptors then becomes important in predicting 
the factors that determine the lethality, poor treatment response and survival of these 
cancers. Normal breast tissues contain receptors that are involved in signaling processes 
which mediate various aspects of cell function and directly influence breast cancer 
growth, proliferation, treatment and prognosis (Buxant, Engohan-Aloghe, & Noel, 2010).  
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                       Table 8: Features of breast cancer molecular subtypes.  
Molecular/Genetic 
Subtype 
Frequency Usual Receptor 
Phenotypes 
Clinical Features 
Luminal A 40% ER+ PR+ HER2- Better prognosis, less recurrence, 
responsive to endocrine treatment 
Luminal B 20% ER+ PR+ HER2+ Younger age than A, larger tumor 
size, lymph node positive, Grade 
II, IV. 
TNBC 15% ER- PR- HER2- Heterogeneity with basal-like (p53 
mutations), BRCA-1, younger, 
Black, poorer prognosis 
HER2 enriched type 15% ER- PR- HER2+ Lymph node +, Grade III, IV, 
Younger age, poor prognosis 
Basal-Like 10% Unclassifiable Mixed features. 
Claudin-low 12% High 
heterogeneity, 
ER+ 
Mixed features, moderate 
prognosis 
Adapted from: Esposito, Criscitiello, & Curigliano, 2015).  
 
TNBC is defined as breast cancer that relatively lacks all of estrogen, progesterone 
receptor-expression and HER2 over-expression (Gluz, Liedtke, Gottschalk, Pusztai, & 
Harbeck, 2009). These protein molecules are receptors that are the phenotypic 
representation of genes that are expressed on breast cancer cells that interact with other 
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protein molecules to carry out specific cell function when activated or inhibited (Rastelli 
& Crispino, 2008). ER, PR and HER2 is their current annotation in the medical literature.  
Occurring with 40% frequency among all breast cancers and the histological cellular 
appearance of the inner lining of mammary ducts and well- or fairly well-differentiated 
tumor cells, they tend to express ER+, PR+ mutations and do not over express HER2 
mutations, respond to hormonal manipulation and in general, carry a better prognosis 
(Rastelli & Crispino, 2008). The Luminal B category tends to have all three receptors 
(Table 8). Of the few that that are HER2-, they tend to have high mitotic rates (high 
ki67). Luminal B also originate in ductal tissue and express ER+ and PR+ mutation but 
with cells that tend to express p53 genetic mutations as well (Ma et al, 2003). The larger 
tumor size and lymph node involvement at diagnosis tend to put these in a fair to poor 
prognosis than Luminal A (Zorka et al., 2014).  
In addition, at diagnosis, histologic grades tend to be in the fair to poorly 
differentiated categories (Zorka et al., 2014). This study will focus on the category in this 
classification in which cancer cells do not express estrogen, progesterone and do not over 
express HER2 receptor mutations (ER-, PR-, HER2 -) (Yanagawa et al., 2012). These 
TNBC tend to overlap with the basal-like immonohistochemical category with which 
there is significant discordance (Gazinska et al., 2013).  Hormonal, other cellular 
receptors and biomarkers are shown in Table 9. 
Specific receptors for the steroid hormones, estrogen and progesterone mediate 
breast tissue cell growth and function through many different signaling pathways. In 
some breast cancers, estrogen and progesterone receptors (ER+ and PR+) are 
overexpressed on malignant cells. ER occur in 65 – 70 % of breast cancers (Nadji et al., 
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2005; Gown et al., 2008) and ER+, PR+ breast cancer cells tend to represent the vast 
majority of breast cancer cells. On the other hand, TNBC (ER-, PR- and HER2-) occur in 
about 10 – 25% of breast cancers from a consensus of multiple small studies and carry a 
worst prognosis than other breast cancer subsets (Rastelli & Crispino, 2008). 
 
          Table 9: List of selective cellular receptors and markers in breast cancer cells. 
RECEPTOR ACRONYM RECEPTOR ROLE 
ER+ Estrogen receptor 
PR+ Progesterone receptor 
HER2/NEU (ERBB2) Human epidermal growth factor receptor 2 
EGFR (HER1) Epidermal growth factor receptor 1 
CK5/6 Cytokeratin 5/6 
P21 Involve both tumor suppression and oncogenic 
modulation* 
KI-67 Proliferation marker of cell mitotic activity 
TOP2 ALPHA Topoisomerase II alpha 
AR Androgen receptor 
P53/63/73 Tumor Suppressor genes 
CXCR7 Chemokine-receptor 7 
*Gartel AL. Is p21 an oncogene? Molecular Cancer Therapeutics, 5, 1385, 2006. 
 
The estrogen-estrogen receptor complex activates messenger proteins through a 
process involving protein activator (AP-1) and specificity protein (SP-1) leading to 
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protein transcription and cell proliferation (Heldring et al., 2003), for both normal cellular 
processes of tissue growth, as well as, oncogenic-tumor suppressive processes (Ma, et al, 
2003). Because breast cancer cell receptors are so intimately involved in cell 
proliferation, treatment and clinical prognosis some knowledge of cell receptor structure 
and function is necessary.  
Structure of Cell Receptors: Cell receptors are structurally part of the cell membrane 
(Lodish, et al., 2000, Section 5.1). The cell membrane is a molecular mosaic principally 
consisting of a bilayer of phospholipid molecules interspersed with other molecules 
including cholesterol, protein and long-chained carbohydrate molecules (Lodish et al., 
2000, Section 15.5). The phospholipid bilayer consists of structural macromolecules, the 
base of which have phosphate moieties dangling intracellularly, while at the other end a 
fatty acid chain extending extracellularly (Lodish et al., 2000, Section 5.1). Lipid soluble 
or hydrophobic ligands can readily cross these bipolar cell membranes. However, water 
soluble or hydrophilic ligands usually bind to specific receptors in order to be transported 
across the cell membrane and into the cytosol (Lodish et al., 2000, Section 15.1).  
Cell receptors are proteins and each have: (1) a surface membrane or ligand-
binding domain, (2) a hydrophobic transmembrane domain and (3) an internal 
intracellular domain that extends into the cytosol region. Transmembrane protein cell 
receptors can bind to other chemicals, as well as other proteins, forming a receptor-ligand 
complex (Lodish et al., 2000, and Section 20.1). Once the receptor-ligand complex is 
formed, the conformational structure of the cell membrane is altered leading to a cascade 
of biochemical changes and the activation or inhibition of signaling pathways (first and 
second messengers). Within the cells are nuclear membrane protein receptors that 
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structurally possess an N-terminal transactivation domain, a middle DNA binding region 
containing a zinc finger domain and a C-terminal ligand binding domain. It is this C 
terminal region that binds to its specific ligand which then binds to promoter elements in 
specific genes that are then activated. Nuclear protein receptors bind to ligands such as 
adrenal hormones including estrogen and progesterone (Zhou & Zingerland, 2014).  
Cell receptors can also be ion channel, G-protein or enzyme-linked receptors. For 
hormone receptors, such as estrogen, that act as growth, oncogenic or tumor suppressive 
triggers in the breast cancer cells, the process starts at the transmembrane molecular 
structure specific for the estrogen molecule. The bound estrogen-receptor complex causes 
a conformational change in the integral membrane proteins activating the G-proteins 
which releases guanine diphosphate (GDP) that is phosphorylated to form guanine 
triphosphate (GTP). The process of conformational change of the integral membrane is 
called signal transduction. Other ligand-receptor binding associated with a specific 
enzyme in its intracellular domain, such as tyrosine kinase causes phosphorylation of 
tyrosine residues in the intracellular domain which can then transmit the signal to the 
intracellular second messenger (Lemmon & Schlessinger, 2011).  
Enzyme-linked receptor activation also occurs with epidermal growth factors 
(EGF), such as HER2. The hormonal pathways often utilize either the 
phosphatidylinositol or G- coupled receptor pathways involving cyclic adenosine 
monophosphate (cAMP) and GDP/GTP phosphorylation pathways (second messenger 
pathway). The second messenger activates proteins and calcium ions from stores in the 
endoplasmic reticulum. The activated proteins travel in the cytosol to the nuclear 
membrane where they bind with receptors and pass into the nucleus activating 
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transcription factors, enabling transcription of proteins. Intracellular binding to regulatory 
DNA sequences activate transcription genes directly or through transcription regulatory 
molecules (Lodish et al., 2000 Section 20.1). The enzyme RNA polymerase separates the 
double stranded DNA helix forming a nucleotide complement to the DNA segment called 
mRNA. The mRNA serves as a template for the synthesis of protein molecules from 
amino acids in the cytosol through a process called translation. 
Ligands like EGF after binding with their specific receptor, induces dimerization 
and autophosphorylation of the epidermal growth factor receptor (EGRR) which in turn 
activates intracellular second messenger signaling pathways. Some of these pathways 
leads to cell division which are mediated by mitogen activated protein kinases (MAPK), 
aberrations of which leads to uncontrolled cell proliferation as seen in some cancers 
including breast cancer (Lodish, 2000, Section 20.1). Complicating this complex process 
are gene modulators, such as Toll-like receptors which act as an on-off switches that can 
amplify the signal leading to induction or suppression of genes and their responses that 
are referred to as toll-gate modulation of gene expression and have implications for 
treatment of cancers including breast cancer (Wang, 2008).  
Biologic Influences of Breast Cancer Subsets among Racial Groups: Are there 
differences in rates of mammary tumor growth, response to chemotherapy, and 
chemoprevention and are there biologic differences particularly hormonal influences – 
such as sex hormones and adrenocorticosteroid hormones - between African Americans 
and white women? Based on current data, definitive answers to these questions are not 
yet available.  
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However, recent research seem to suggest that in African Americans women 
breast cancer appears to be more aggressive and lethal than in White women. It is 
established that African American women are also more likely to present with breast 
cancer at a younger age than White women (Chlebowski et al., 2005). Analysis of data 
from the Women's Health Initiative study revealed that African American women had 
more high-grade and estrogen receptor negative tumors, at a rate five times higher than 
for White women. Both findings make these aggressive breast cancers more difficult to 
treat and are associated with poorer outcomes (Chlebowski et al., 2003; Li et al., 2002; 
Miller B, et al., 2002).  
Adding to this are early genetic studies that address differential susceptibilities. 
Mutations in the TP53 gene were more common in African American women than in 
White women with breast cancer, based on a recent population-based study. Mutations in 
the TP53 tumor suppressor gene are associated with cancers that grow faster, are more 
likely to spread, and have a poorer prognosis (Jones et al., 2004).  TNBC through HER2 
activation is known to stimulate breast cancer cellular growth and is amplified and/or 
over expressed in about 20-25% of invasive breast cancers. These cancers tend to grow 
faster, spread more rapidly, recur more often, and have a poorer prognosis than other 
breast cancers (Weiss et al., 2006). 
New data on cancer biology point to a critical role of gene expression in the 
development of cancer. Cancer can be described as the uncontrolled growth of abnormal 
cells. Usually a network of signals that promotes cell division through oncogenes, control 
cell growth by slowing or stopping cell division at the right time (tumor suppressor 
genes), or repairing DNA damage. DNA damage can affect gene amplifications, gene 
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deletions, point mutations, loss of heterozygosity, chromosomal re-arrangements, and an 
abnormal number of chromosomes (NCBI, 2005; Dickson et al., 2000). Moreover, breast 
cancer development can be triggered by mutations of the signals in the network that 
controls cell division, and can be associated with genetic predisposition (e.g., mutations 
in the BRCA1 and BRCA2 genes), exposure to some environmental factor (e.g., radiation 
exposure of the chest), or both. While large-scale studies of variation in network 
signaling among races are lacking, a better understanding of cancer biology and how it 
differentially affects certain races point out the necessity for a better understanding of the 
role of human genetics in breast cancer biology. 
Interaction of Race, SES and Biology in Breast Cancer Survival: Once a diagnosis of 
invasive breast cancer is made survival becomes dependent on a number of factors. Some 
of these factors are similar to known risk factors for developing the disease. These 
include: disease stage at diagnosis, time since diagnosis, race and ethnicity and 
socioeconomic factors.  
By definition the longer one lives after diagnosis the higher the survival rate for 
that breast cancer subset. Among women who survived 5 years after diagnosis, the 5 
years survival rate is 87 % (85% for black women). For women surviving 10 years 
following diagnosis, the 5 year survival is 77%. There is clear evidence that earlier 
diagnosis leads to longer survival. If the disease is diagnosed when localized to the breast 
there is a 97% five-year survival. However, if the disease has spread to distant sites the 
five year survival is only 23% indicating that the stage at diagnosis predicts survival.  
Race and ethnicity also play a major role in survival. However, race and ethnicity 
may be more complex as risks of survival than currently understood. They may be 
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intertwined with income, treatment and health insurance availability, genetic and 
environmental factors. Still race and ethnicity is one independent factor that influences 
breast cancer survival. Black women 5 year survival is 74% compared to white women 
85% (Howlader et al., 2012)). African American women tend to be diagnosed at a more 
advanced stage of the disease than white women. Moreover, even when compared to 
women diagnosed at the same stage of the disease the outcomes of African American 
women are still poorer.  
Lack of health insurance certainly plays a role in this lower breast cancer survival 
among black women. This may be a surrogate for income since among black women, 
five- year survival is lower among low income black women when compared to higher 
income black women. Moreover, there is a gradient of 5-year survival based on income 
such that lower income women irrespective of race also have a lower 5-year survival than 
higher income women. Disparities in treatment options offered women of different races, 
access to medical care and co-morbid conditions also appear to directly influence race-
specific five year survival. 
 
iv. Breast Cancer Clinical Stages and Grades 
 
 
The main aim of this study is to evaluate the factors that predict survival in breast cancer 
and its phenotypes. The extent of spread of breast cancer cells to a large extent clearly is 
expected to determine survival. In fact, estimation of prognosis has been correlated with 
the extent of breast cancer disease based on clinical evaluation at the time of diagnosis 
(Tot et al, 2011). The extent of spread of breast cancer cells to a large extent determines 
35 
 
survival. Estimation of prognosis has been correlated with the extent of breast cancer 
disease based on clinical evaluation at the time of diagnosis. The determination of the 
extent of breast cancer is called staging. The stage or extent of disease also aids treatment 
and guides prognostication. Treatment of breast cancer is complex. It depends on tumor 
size (<2cm, 3 – 5cm, > 5 cm), hormonal receptor status (ER+, PR+, HER2, triple 
negative), patient age (premenopausal vs. postmenopausal), stage (disease extent), grade 
and gene type. Below (Table 10) is a grid of AJCC breast cancer stage classification 
(Breast. In: Edge SB, Byrd DR, Compton CC, et al, eds.: AJCC Cancer Staging Manual. 
7th Ed. New York, NY: Springer, 2010, pp 347-376). 
                            Table 10:  AJCC - TNM breast cancer classification by stage. 
 
Stage Explanation Tumor Size Nodes Metastasis 
I Small and limited to breast or 
sentinel lymph node N0 or N1mi  
A. < 2 cm, no lymph nodes 
B. < 2 cm, local lymph nodes 
cancer cell cluster < 0.2 
mm 
T1mi 
Ta 
Tb 
Tc 
N0 
N1 
M0 
(No clinical metastasis) 
II Larger tumors with spread to 
regional lymph nodes 
A. Less than 2 cm 
B. More than 2 cm but < 5 
cm, < 3 local lymph 
nodes  
T2 N2 
N2a 
N2b 
M0 
III A. Larger and operable, < 
9 regional lymph nodes 
B. Larger and inoperable 
C. Spread to > 9 regional 
lymph nodes  
T3 N3 
N3b 
N3c 
N3d 
M0 
IV Metastasized to bones, liver, 
lungs, etc. 
T4a 
T4b 
T4c 
T4d 
 M1 
(Distant Metastasis 
Clinically) 
 
Even though this has been found simplistic as a guide to treatment (Veronesi et al., 2009) 
it is still useful for prognostication.  
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Histological Grade: The Nottingham Grading System is considered the gold standard of 
histological breast cancer grading (Elson & Ellis, 1991). In this system, tumor grade 
classification is founded on the histological characterization of cancer cells based on 
degree of homology and differentiation from normal breast terminal-duct lobular tissue 
(Table 11). Tumor grade has been correlated with prognosis and a number of breast 
cancer characteristics (Rakha et al., 2010) but breast cancer grading is principally used 
for prognostic assessment. 
 
                      Table 11: Tumor grade and relative prognosis. 
Grade Differentiation Prognosis 
1 Well differentiated Better 
2 Moderately differentiated Fair 
3 Poorly differentiated Poor 
4 Undifferentiated Poorest 
 
 
v. Consensus Standard Treatment of Breast Cancer 
 
The main aim of this study is to evaluate the factors that predict survival in breast cancer 
and its phenotypes. One of the factors determining breast cancer survival is the treatment 
administered following diagnosis. Who is treated and with what is a major determinant of 
breast cancer survival. The standard of care for breast cancer treatment has and continues 
to change over the course of history. The current approach will be summarized below.  
First some definitions: 
1. Adjuvant therapy: This is used for prophylaxis against potential recurrence or 
spread and after surgery and includes (1) radiation therapy to regional lymph 
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nodes and to chest wall (locoregional radiation therapy), (2) Systemic therapy 
with endocrine agents for ER+, PR+, chemotherapy, and monoclonal antibodies 
especially for HER2+ breast cancer which can be combined with chemotherapy.  
2. Targeted neoadjuvant therapy: This is administered to shrink tumor size after 
needle biopsy but before other surgery of any kind (Metzger-Filho & de 
Azambuja, 2011). 
History of Breast Cancer Treatment: In 1882 William Halstead introduced into the United 
States what then became the accepted standard treatment for breast cancer for almost a 
century, the radical mastectomy (Rankin J., 2006). The degree of node dissection, 
including axillary node dissection, became more extensive over time. As early as 1962 in 
Europe (Kaae & Johansen, 1962; Kaae & Johansen, 1969), there was an indication of no 
difference in breast cancer outcome between the radical mastectomy and the combination 
of BCS and radiation by the McWhirter method.   
In the US, Fisher first reported the effectiveness of limited mastectomy plus 
radiation therapy compared to the radical mastectomy for early stage breast cancer in 
studies beginning in 1971 (Fisher B, Montague E, Redmond C, Barton B, et al, 1977). 
Still it took some time for the BCS plus radiation therapy to become the mainstay of 
treatment for early stage breast cancer of all subtypes, which it still is today. In 1975 
Fisher et al. (1975) and Bonadonna et al. (1975) reported the effectiveness of adjuvant 
chemotherapy after surgery to increase breast cancer survival (Fisher et al., 1975; 
Bonadonna, Brusamolino, Valagussa, & Veronesi, 1975).  Even before the discovery of 
hormone receptors, ovarian hormone suppression through oophorectomy and ovarian 
ablation was used to improve breast cancer survival from 1940 to 1960 (Love & Philips, 
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2004; Singh, 2012; Prowell & Davidson, 2007). With the discovery of the estrogen 
receptor and its use to predict risk of breast cancer recurrence, the next major step in 
endocrine therapy occurred when the FDA approved the use of the selective estrogen 
receptor modulator (SERM) tamoxifen in 1977. In 1986 it was reported that tamoxifen 
could be effectively given prophylactically against breast cancer recurrence when 
administered for five years after surgery in postmenopausal women and increase survival 
(Delozier et al., 1986).   
In the early part of this century, molecular profiling was used to classify breast 
cancers into genetic subtypes and predict the risk of early breast cancer recurrence (Sorlie 
et al., 2001). This has led to the use of endocrinological treatment as adjuvant therapy for 
Luminal A breast cancer subsets which has significantly improved breast cancer 
outcomes (Goldhirsch et al., 2011). Moreover, combination systemic therapy proved to be 
effective for Luminal B, HER2+ and TNBC subsets as adjuvant therapy in enhancing 
breast cancer survival (Goldhirsh et al., 2011). 
Today surgery, radiation and multimodal systemic treatment are now accepted as 
the current standard of care for breast cancer based on a variety of factors (NCI, 2015). 
These factors include tumor size, stage of disease, patient’s age and menopausal status, 
breast cancer cell receptor status, gene type (BRCA mutation), and tumor histologic 
grade. Stage is one of the single most important factors determining optimal breast cancer 
treatment. In 1979 the American Joint Committee on Cancer (AJCC) staging 
recommendations utilized the previously established TNM system in its first manual, a 
summary of which was shown in Table 11 (Breast. In: Edge SB, Byrd DR, Compton CC, 
et al, eds.: AJCC Cancer Staging Manual. 7th Ed. New York, NY: Springer, 2010, pp 347-
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76). The evolution of breast cancer treatment from surgery, radiation therapy, 
chemotherapy, endocrine therapy and to biological therapy over the years have brought 
us to the present and has become the mainstay of breast cancer treatment currently. 
Current Standard of Care Treatment: The NCI sponsored ESMO expert consensus 
treatment guidelines and the St Galen International Breast Cancer Conference (2011) 
Expert Panel on breast cancer treatment by subsets is summarized in Table 12 (Aebi, 
Davidson, Gruber & Cardoso, 2008; Goldhirsh et al., 2011).  
 
                   Table 12: Specific treatment of breast cancer by subtype.  
Breast Cancer Subset Classification Specific Treatment 
Luminal A Endocrine therapy 
Luminal B Chemotherapy 
Endocrine therapy 
HER2 + Biological therapy (Trastuzumab) 
Triple Negative Chemotherapy 
 
This summary in Table 12 below excludes the treatment of inflammatory breast 
cancer and recurrent breast cancer. It also excludes the standard neoadjuvant or adjuvant 
systemic therapy given in conjunction with initial surgical plus locoregional radiotherapy, 
which is considered standard initial treatment for early breast cancer. Invasive TNBC and 
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NTNBC comprehensive treatment options based on menopausal and hormonal cell 
receptor status are summarized separately in Table 13.  
Surgery: In general, for earlier stage invasive breast cancer (Stage I, II, IIIB and IIIC) and 
small tumor size (< 5cm), BCS has evolved as the accepted surgical approach for breast 
cancer primarily because it results in the best survival and quality of life (Fisher et al., 
2006; Cao, Olson & Tyldesley, 2013). The BCS procedure of choice for earlier stage 
disease is the “lumpectomy” in which the tumor is removed with or without regional 
lymph node dissection together with radiation therapy (Solin, 2010). A partial 
mastectomy is also considered BCS surgery for larger sized tumors (Rahman, 2011) and 
is often utilized based on cell receptor status and may even show improved survival over 
a total mastectomy (Parker, Lin & Shen, 2014). The BCS has supplanted the radical 
mastectomy as the standard surgical procedure that was performed before the 1990s for 
most stages of breast cancer (Loukas et al., 2011). Since then, data has suggested that the 
survival rates from radical mastectomy were no different than that of combined BCS and 
radiation therapy for earlier stage disease (Anderson et al., 2009).  
Besides this lack of outcome-difference between the BCS and more disfiguring 
aggressive surgeries, BCS also offers the benefit of a better quality of life, wellbeing, less 
fear of loss of femininity, sexual desirability, less depression and a sense of isolation 
(Moyer A et al., 1997; De Haes, Van Oostrom, & Welvaart K, 1986; Nissen et al., 2001; 
Ganz, Rowland, Desmond, Meyerowitz, & Wyatt., 1998). Post-surgery, women had more 
positive body image with BCS than otherwise (Steinberg, Juliano, & Wise, 1985; Mock 
et al., 1993. The loss of chest wall muscle mass and muscle strength was also less with 
BCS than radical mastectomy (Wellisch & Dimatteo, 1989; Crosbie et al., 2010). 
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There are still some surgical indications for total mastectomy. The National 
Comprehensive Cancer Network guidelines for mastectomy indications include the 
following: prior radiation therapy to the breast or chest wall, when radiation therapy is 
contraindicated by pregnancy (except patients in the third trimester who can receive 
radiation postpartum), inflammatory breast cancer, diffuse suspicious or malignant-
appearing microcalcifications, widespread disease that is multicentric, located in more 
than one quadrant, and cannot be removed through a single incision with negative 
margins and a positive pathologic margin after repeat re-excision and suboptimal 
cosmetic outcome. Some relative indications for mastectomy as opposed to BCS, include 
active connective tissue disease involving skin, like scleroderma or systemic lupus 
erythematosus (SLE), breast tumors greater than 5 cm in diameter and focally positive 
surgical margins (NCCN, 2014).  
Systemic Therapy: Radiation, endocrine, biological and chemical agents are systemic 
forms of therapy, which when administered after surgical treatment, are broadly 
considered adjuvant therapy (Chew et al., 2001). Adjuvant therapy as previously defined 
is secondary therapy following initial therapy with the goal of suppressing or preventing 
spread of neoplastic residues or micrometastasis (Hortobagyi et al., 2001). 
Radiation is indicated as adjunctive therapy for BCS or mastectomy depending on 
lymph node involvement and/or the size of the primary breast lesion (>5cm) and even for 
metastatic breast cancer (Clarke et al., 2005). Radiation can be administered either as an 
external beam or internally as brachytherapy. Externally administered radiation can be 
applied focally or extensively and is considered the standard of care for radiation therapy. 
Brachytherapy is usually applied locally by interstitial or intracavitary radioactive pellets. 
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Intracavitary brachytherapy is now becoming the approach of choice for locally 
administered therapy, although its efficacy versus external beam therapy still has not been 
adequately established (Smith et al, 2013). Radiation can be administered at various 
stages before or after surgery, all of which carries specific risks and benefits.  
Because TNBC is relatively unresponsive to hormonal manipulation, systemic therapy is 
the treatment of choice following surgery and locoregional radiotherapy for TNBC, and 
for advanced stage breast cancer with widespread metastasis. Systemic therapy is also 
indicated for inoperable breast cancer where the disease is too extensive at the time of 
diagnosis (Cardoso et al., 2012).  
Chemotherapy drugs for breast cancer is always evolving and currently includes 
agents such as Adriamycin, cyclophosphamide, cisplatin, vinblastine, 5-fluorouracil 
(5FU), epirubicin, paclitaxin, doceaxel, vinorelbine, capecitabine, and gemcitabine. 
Endocrine therapy is often employed when breast cancer cell receptors indicate 
cancer is amenable to this type of therapy, which is, with the presence of estrogen, 
progesterone and androgen receptors (Burnstein et al, 2014).  
 
      Table 13: Treatment of early breast cancer by receptor and menopausal status. 
 
ER+/PR+ 
(Premenopausal) 
ER+/PR+ 
(Postmenopausal) 
HER2+ Triple 
Negative 
Surgery 
Locoradiation 
Surgery 
Locoradiation 
Surgery 
Locoradiation 
Surgery 
Locoradiation 
Endocrine Therapy 
(SERM) 
Endocrine Therapy 
(Aromatase Inhibitors) 
Monoclonal Antibody Chemotherapy 
Examples:    
    Tamoxifen 
    Toremifene 
    Fulvestrant 
Examples: 
     Anastrozole 
     Letrozole  
     Exemestane 
Examples: 
     Trastuzumab 
     Bevacizumab       
(? Biological 
therapy) 
 
43 
 
For premenopausal women with breast cancer and the appropriate receptor status, 
endocrine therapy includes the now outdated oophorectomy and the more recent SERM, 
such as tamoxiphen, toremifene and fulvestrant. For postmenopausal women and the 
appropriate receptor status aromatase inhibitors, such as anastrozole, letrozole and 
exemestrane, are often utilized for specific treatment. Table 13 summaries use of 
endocrine therapy based on menopausal and cell receptor status. Biological therapy is 
quickly becoming a useful and effective form of treatment for many forms of cancers 
including colorectal, renal cell and non-small cell lung cancers (Shih & Lindley, 2006). 
As systemic therapy for breast cancer, its effectiveness is being studied currently.  Agents 
such as trastuzmab have found widespread utility for HER2 positive breast cancer 
(Goldhirsh et al, 2011). Trastuzmab inhibits the HER2 up-regulation by direct HER2 
degradation and antibody-dependent cellular cytotoxicity (Vu & Claret, 2012). The 
effectiveness of bevacizumab, an inhibitor of angiogenesis through inhibition of vascular 
endothelial growth factor, for TNBC and other  breast cancer phenotypes is less 
encouraging, except for as adjunctive treatment in combination with other agents for 
select forms of breast cancer and particularly metastatic breast cancer (Valachis et al., 
2010; Smith et al., 2011).   
 
Treatment of Triple-Negative Breast Cancer: The main aim of this study is to evaluate the 
factors that predict survival in breast cancer and its phenotypes and treatment is one of 
those factors.  In general, the treatment outcome for TNBC compared to other subsets of 
breast cancer is poorer irrespective of treatment administered (Dent et al., 2007). The use 
of standard protocols for treating Luminal A and B, subsets of breast cancer has not met 
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with the same success in treating TNBC (Andre & Zielinski, 2012). BCS plus radiation, 
has shown a low recurrence rate for TNBC compared to NTNBC in some studies, with 
higher rates of recurrence in others (Freedman et al., 2009; Haffty et al., 2006; Schwartz 
et al., 2005). Unlike Luminal A and Luminal B classes of breast cancer where endocrine 
therapy has been found relatively effective, in the basal-like breast cancer analogues, 
including TNBC, endocrine therapy has had poor outcomes either as separate or as 
adjuvant form of treatment (Hudis & Gianni, 2011). Systemic therapy especially 
chemotherapy shows the best promise in treating TNBC (Andre & Zielinski, 2012). 
Moreover, because clinical trials involving systemic therapy are still ongoing, definitive 
consensus protocols have not been clearly established but are evolving. Despite the 
paucity of available supportive data on effective treatments for TNBC, a consensus is 
developing about a reasonable approach to treating TNBC in the face of these many 
limitations. Current recommended treatment for TNBC is systemic chemotherapy 
following BCS and locoradiation therapy (Schwartz et al., 2006).  
 This is also the recommendation of the National Cancer Institute expert consensus 
for TNBC treatment (National Cancer Institute National, 2015). BCS surgery in 
conjunction with locoradiation therapy has been found to be as effective in TNBC as non-
TNBC with the same rates of recurrence (Freedman, Anderson, Li, & Nicolaou, 2009). 
Despite this, recent data suggested that in actuality patients with TNBC were undergoing 
more extensive mastectomy at a higher rate than other breast cancer subtypes (Lizarraga, 
Schroeder, Weigel, & Thomas, 2015).  
Systemic therapy as currently used, is also evolving with the use of taxanes, 
anthracycline and platinum salts (Isakoff, 2010; Yadav, Sharma, Chanana, & Jhamb, 
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2014). For earlier stages, anthracycline-based regimens (like doxorubicin) followed by 
docetexel is currently being utilized by some (Yadav et al, 2014). Some experts prefer the 
combination of docetaxel and cyclophosphamide (Martin et al, 2010). For higher stages 
of TNBC with metastasis, platinum compounds (cisplatin or carboplatin) and PARP 
inhibitors (gemicitabine or olaparib) are being utilized (Niu, Sangal & Quan, 2014). 
Angiogenesis inhibitors like bevacizumab have not been as effective as they are in colon 
and lung cancers (Cameron et al, 2013). Newer regimens are currently in trials including 
the biological EGFR inhibitors (Ueno & Zhang, 2011), as well as PARP (O’Shaughnessy 
et al., 2014), alpha B-crystallin (Altundag et al., 2007) and cyclin dependent kinase 
inhibitors (Ueno & Zhang, 2011). 
For the purpose of this study, the accepted standard of care for early stage TNBC 
will be the NCI recommended standard of care. The SEER database only contains 
surgical procedures and radiation therapy as breast cancer treatment options. As a result 
with these limitations in mind and for the purpose of this study, appropriate treatment of 
TNBC will include BCS plus radiation therapy.  
 
vi. Epidemiology of Triple-Negative Breast Cancer 
 
 
The main aim of this study is to evaluate the factors that predict survival in breast cancer 
and its phenotypes, and it requires an understanding of the epidemiology of these 
phenotypes. As will be discussed later in the next section on “Knowledge Gaps,” the 
epidemiology of TNBC is not well known (Gierach, Burke, Anderson, 2010; Boyle, 
2012) and the burden of TNBC in the general population is still unclear (Dolle et al., 
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2009). This is not surprising since the distinction between breast cancer molecular 
subtypes was only first reported in 2000 (Perou et al., 2000). Most of the currently known 
TNBC epidemiological estimates have been based on relatively small datasets rather than 
large population studies like the one here. Except for one study (Howlader et al., 2014) 
most of the current epidemiological estimates of incidence, prevalence and mortality of 
TNBC are based on findings from small samples, observational studies, limited 
geographical areas, hospital or state cancer registry datasets (Carey et al., 2006; Bauer et 
al., 2007; Lund et al., 2009; Moran, et al., 2006). This makes generalizability to the larger 
population difficult. 
Incidence and Prevalence: Only one large population-based study has estimated age-
specific incidence rates for TNBC but that study was based on one-year study-data only 
(Howlader et al., 2014). The authors reported age-specific incidence rates for TNBC for 
the year 2010 among 50,571 known breast cancer subtypes using SEER registries 
representing 28% of the US population. The peak incidence rate was 69.5 per 100,000 in 
non-Hispanic Blacks between ages 65 and 69 years compared to 36.8 per 100,000 in non-
Hispanic whites, 23.6 per 100,000 in Non-Hispanic Asians/Pacific islanders and 32.6 per 
100,000 among Hispanics.  
In studies greater than one year study duration, but smaller population datasets, 
the proportion of breast cancer patients with TNBC represented between about 10 – 20 % 
of invasive breast cancers (Carey et al., 2006; Dawson, Provenzano, & Caldas, 
2009; Morris et al., 2007). While trends in overall breast cancer incidence and prevalence 
are well-known and reported (ACS, 2012) that is not the case with TNBC (Boyle, 2012). 
One population-based study (Howlader et al, 2014) provided reasonably good estimates 
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of TNBC in various population subsets. In that study, non-Hispanic black women had the 
highest incidence of TNBC across all age groups with the widest disparity occurring 
between ages 64 – 69 years compared to other racial groups. 
Age Distribution: A number of studies have reported that younger age at diagnosis is a 
putative risk factor for TNBC. In a descriptive study utilizing data from the California 
Cancer Registry of 375, 761 invasive breast cancer patients, Amirikia et al. (2011) found 
that women, age less than 44 years had higher incidence rates of TNBC than all other 
breast cancers (Amirikia et al., 2011). In a cohort study, Bauer et al. (2007) also using 
data from the California Cancer Registry compared 6370 TNBC women with 44,704 
women with other cancer subsets found an association between TNBC and being younger 
than 40 years old [OR 1.53 (95% CI 1.37 – 1.70)].  
In a smaller rural West Virginia Hospital-based registry descriptive study, among 
620 breast cancer patients 117 had TNBC (Vona-Davis et al., 2008). They found patients 
with TNBC were younger (44.5%) than those with other receptor subtypes (26.7%) p < 
0.0004. In a prospective cohort study from Toronto (Dent et al., 2007), of 180 TNBC 
cases among 1601 invasive breast cancers, the mean age at diagnosis was significantly 
younger for the triple-negative group compared with other breast cancers (53.0 versus 
57.7 years, respectively; P < 0.0001).  
Another, the Carolina Breast Cancer Study (Carey et al., 2006) has reported age 
distribution estimates confirming the young age distribution of basal-type breast cancer 
compared other molecular subsets. One large population-based study yielded useful age 
distribution estimates (Howlader et al., 2014.). Results of that study showed that TNBC 
tends to occur in younger ages at diagnosis compared to other molecular subtypes (Table 
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14). In that study, as in the present study, hormonal receptor status (HR+) consisted of 
combined ER+/PR+ status. The same study, suggests that the incidence of TNBC is not 
only higher in younger premenopausal African American women but remains higher in 
all age and racial/ethnic groups, including those in postmenopausal white women. This is 
not the case with overall breast cancer incidence versus age-comparisons, where there is a 
crossover of incidence and where breast cancer incidence becomes higher in white 
women compared to African American women after age 50 years (NAACCR, 2011, 
Howlader et al., 2011). 
 
                Table 14: Invasive TNBC age-distribution among case patients.  
Age Group 
(Years) 
TNBC 
(Cases) 
TNBC 
(% Cases) 
HR+/HER2+ 
(Cases) 
HR+/HER2+ 
(% Cases) 
< 50 1616 15.2 1528 14.4 
50 – 64 2540 13.2 2066 10.7 
65 – 74 1151 10.4 939 8.5 
≥75 866 9.3 707 7.2 
Data for 2010 (N = 6193). Taken from: Howlader et al., 2014. 
 
Mortality: Few studies on disparities in TNBC mortality rates have also been reported 
previously. A few small studies have reported that proportionally, the mortality of TNBC 
is increased for this subset of breast cancer compared to all other breast cancer subtypes 
(Carey et al.; Dent et al; and Solie et al., 2003) but mortality rates from large populations 
have not been reported for TNBC.  
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One of the largest studies reported so far, with N = 9908 TNBC patients, found 
that elderly patients ≥ 70 years old with TNBC showed an increased early mortality 
within the first two years of diagnosis compared to younger individuals < 70 years old 
which could be attributed in part to a lower rate of loco-regional radiotherapy in the 
elderly compared to younger age-groups (Zhu, Perez, Hong, Li & Xu, 2015).  
Trends: While trends in overall breast cancer incidence, prevalence and mortality are well 
known (ACS, 2012) that is not the case with TNBC and other breast cancer subsets 
(Boyle, 2012).  Data on secular trends and changes in epidemiological indices over time 
still has to be better delineated for TNBC and other subsets. 
Survival: It has been reported in some smaller studies that survival in TNBC is worse 
than in other subsets. In part, this may be due to the finding that TNBC tends to be first 
diagnosed at a late stage of the disease (Morris et al., 2014). Even when it is diagnosed 
earlier, TNBC responds poorly to conventional modes of therapy, is insensitive to 
endocrine therapy and currently available monoclonal antibodies (Oakman C, Viale G 
and Di Leo A, 2010). It is a more aggressive cancer with a higher Ki67 index of cellular 
proliferation and higher mitotic rates than other breast cancer subsets (Carey et al., 2006). 
It also has a higher rate of recurrence (Dent et al., 2007) and readily metastasizes to 
distant sites (Liedtke et al., 2008) and visceral organs including the brain than other 
breast cancer subsets (Hicks et al., 2006; Dent et al., 2007).  
In one study the five-year relative survival of TNBC compared to other breast 
cancers was 14% higher (Bauer et al., 2007). In another, the five year survival was 81% 
compared to 94% for ER/PR+HER2- breast cancers (Kaplan & Malmgren, 2008).  
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Overall survival is worst with TNBC compared to other subsets (hazard ratio 1.8 (95% CI 
1.06 – 3.2) (Onitilo, Engel, Greenlee & Mulesh, 2009). 
Disease-free survival was also worst compared to other subtypes (hazard ratio 1.5 [(95% 
CI 0.8 – 3.0)] (Kaplan & Malmgren, 2008). TNBC has double the recurrence rate 
compared to other breast cancer subsets (Billar et al., 2010). In one study, (Dent et al., 
2007), the risk of recurrence of TNBC is higher the first 3-5 years after diagnosis. 
BRCA1 genotype is strongly associated with TNBC with about 20% of women with 
TNBC having the BRAC1 genotype, while the converse association found that 48% of 
BRAC1 mutations carriers have TNBC, compared to 12% in non-carriers of the mutation 
(Lee et al., 2011).  
 
            Figure 5: Breast cancer survival from the Carolina Breast Cancer Study. 
 
Frequencies: luminal A = 51%, luminal B = 16%, basal-like = 20%, HER2+/ER− = 7%, and 
unclassified = 6%. 
 
 
           Taken from: Carolina Breast Cancer study (Carey et al., 2006). 
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Survival estimates for selective breast cancer subtypes has been reported in the 
Carolina Breast Cancer study (Carey et al., 2006). The data from that study is shown in 
Figure 5 which illustrates the findings that the disparity in survival for basal-like breast 
cancer is worse than that for other subsets. Compared with other women with breast 
cancer the likelihood of death within five years of diagnosis was increased for basal-like 
breast cancer [hazard ratio 3.2, (95% CI: 2.3- 4.5); p < 0.001].   
Preliminary one-year survival rates for the year 2010 were reported in one study in 
abstract form showing no difference in survival rates among ethnicities. The authors 
emphasized that follow-up data greater than one year was needed to reach more 
meaningful conclusions (Rushton, Zhang & Song, 2014). 
Race and Ethnicity: The prevalence of TNBC was estimated as 26% in African American 
women compared to 16% in white women (Carey et al., 2006).  
 
                  Table 15: Racial/ethnic distribution of invasive TNBC year 2010.  
Race/Ethnicity Group Cases Cases (%) 
Non-Hispanic Whites 3850 10.7 
Non-Hispanic Blacks 1183 22.5 
Non-Hispanic Asian/ Pacific Islander  376 9.7 
Hispanic 727 14.7 
Total 6193 100 
Taken from: Howlader et al., 2014. 
 
52 
 
Among premenopausal women in the same study the frequencies were 39% among 
African American women and 16% in the rest of the sample of non-African American 
women (p < 0.001). Population-based prevalence data per 100,000 has not been reported. 
Recent data suggests that Hispanic women also may be at higher risk of TNBC than that 
reported in white women (Howlader et al., 2014; Lara-Medina et al., 2011). The 
disparities in risk, incidence, mortality, and survival between Hispanic and non-Hispanics 
have not been well-studied. In contrast, the disparity data in TNBC-disease risk between 
racial groups is only slightly clearer, and again not definitively so. See table 15 which 
shows the race/ethnic distribution of TNBC in year 2010 case-based analysis. 
In some studies, African American women have up to a 3 times greater risk of developing 
TNBC than does other population subsets (Lund et al., 2009). In the study by Carey et al., 
(2006), it was estimated that TNBC occurs in 39% of African American women 
compared to 16% among white women (p 0.001) (Carey et al., 2006). The study by 
Morris, et al., (2007) yielded a similar disparity with 20.8% among African American 
women compared to 10.4% among white women (p <0.0001). Moran et al., (2008), 
showed a 21% versus 8% disparity (p< 0.001). A smaller study showed a 28% versus 
12% disparity (p< 0.001) (Sturtz et al., 2014).  
In one population- based study, it was estimated that 47% of breast cancer in 
African American women were TNBC while only 22% was the case in white women, 
p<0.001 (Lund, et al., 2009). Even in an international study involving women of African 
ancestry, the racial disparity persisted (Stark et al., 2010). Premenopausal women tend to 
be at greatest risk of developing TNBC and up to 39% of all African American 
premenopausal women have TNBC (Carey et al., 2006). 
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Genetic and Histologic Disparity: TNBC patients tend to have breast cancer with higher 
histologic grades, Ki 67 and higher mitotic indices (Carey et al., 2006). Breast cancer in 
women with BRCA-1 mutation is more likely to be TNBC (Sorlie et al., 2003). It has 
been reported that up to 75% of breast cancers that develop in BRCA1 mutations carriers 
are triple-negative (Bayraktar et al., 2011; Atchley et al., 2008; Musolino et al., 2007). 
Atchley et al. (2008) found an incidence of 51% triple-negative among BRCA1 mutation 
carriers. The converse is also significant in that other studies suggest that in a population 
of TNBC patients, the proportion of BRCA1 mutation in certain patient population is 10 
– 30% (Evans et al., 2011; Gonzalez-Angulo et al., 2011). Only studies of small sizes 
have demonstrated this high prevalence of BRCA1 mutation among TNBC patients.  
Risk Factors: Only a few risk factors for TNBC have been clearly delineated in the 
literature. They include younger age at diagnosis (Amirikia et al., 2011), Black race 
(Bauer et al., 2007; Carey et al., 2006; Kurian et al., 2010), Hispanic ethnicity (Bauer et 
al., 2007), high BMI (Stead et al., 2009; Kwan et al., 2009; Vona-Davis, et al., 2008), 
delayed age at menarche (Phipps et al., 2011), higher parity (Kwan et al., 2009; Shinde et 
al., 2010; Phipps et al., 2011), reduced breastfeeding (Kwan et al., 2009; Shinde et al., 
2010), oral contraceptive use (Dole et al., 2009), BRCA1 mutation, and premenopausal 
status (Carey et al., 2006; Sorlie et al., 2003).  
In contrast with other breast cancer subtypes, high parity and young age at first 
birth, lack of breast feeding and early age of menarche are risk factors for TNBC 
(Millikan et al., 2008; Phipps et al., 2011; Yang et al., 2007) especially among African 
American women (Ambrosone et al, 2015). TNBC patients tend to live in counties with 
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higher poverty levels, as shown in the only large one-year study to demonstrate this 
geographic disparity (Howlader et al., 2014). 
Weight and Obesity: In the study by Kwan et al. (2009), the investigators also found that 
more women with the TNBC subset tended to be overweight than those with the luminal 
A subset [OR = 1.82 (95% CI 1.03 – 2.81)] and to be obese if premenopausal with OR 
1.97 (95% CI 1.03 – 3.77). The smaller Appalachian-based study by Vona-Davis et al. 
(2008), found that 49.6% of women with TNBC were obese compared to 35.8% of those 
with non-TNBC women being < 50 years (p < 0.0004). An Atlanta-based study consisting 
of the Atlanta arm of a multicenter population-based case control study of breast cancer 
risk factors with patients from Metropolitan Atlanta, Georgia comprising Cobb, Fulton or 
DeKalb counties, (Trivers et al., 2009) found that women with TNBC were more likely to 
be obese than normal/underweight (OR=1.89, 95% CI 1.22–2.92). 
Genetics and BRCA1 Mutation: This has been discussed previously. It was reported that 
up to 75% of breast cancers that develop in BRCA1 mutations carriers are triple-negative 
(Bayraktar et al., 2011; Atchley et al., 2008; Musolino et al., 2007). Atchley et al. (2008) 
found an incidence of 51% triple-negative among BRCA1 mutation carriers. The 
converse is also significant in that studies also suggest that in a population of TNBC 
patients the prevalence of BRCA1 mutation is 10 – 30% (Evans, et al., 2011; Gonzalez-
Angulo, et al., 2011).  
Endocrinological Factors: The study by Li et al. (2013) was based on data collected from 
cancer registries in the Seattle, Puget Sound area, yielded 1056 study patients and 941 
randomly selected controls. 180 TNBC patients were extracted and included for analysis. 
An inverse relationship was observed between breastfeeding, age at first menarche, and 
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age at first live birth when TNBC was compared with controls (Li et al., 2012). Early age 
at menarche, shorter duration of breast-feeding, younger age at full-term pregnancy were 
risk factors for basal-like TNBC in the Carolina Breast Cancer Study (Carey et al., 2006). 
In the Women Health Initiative study (Phipps et al., 2011) among parous women having 
three or more births versus one birth was associated with TNBC (Hazard Ratio =1.46, 
95% CI 0.82–2.63. High parity and early age at first birth were also risk factors in TNBC 
compared to other breast cancer subsets where nulliparity and delayed age at first birth 
were risk factors (Yang et al., 2005). The study by Kwan et al. (2009) found that the 
TNBC subset tended to not have breastfed if the parity was ≥ 3 (OR=1.68, 95% CI 1.00–
2.81). In the study by Shinde et al. (2010) women with TNBC had a shorter duration of 
breastfeeding per child (OR=0.93, 95% CI 0.90–0.97) and a higher parity (OR=1.12, 
95% CI 1.06–1.20) than non-TNBC women (Shinde et al., 2010). Using data from the 
cancer registries in the Seattle, Puget Sound area, a case control study of 187 TNBC 
patients by Dolle et al. (2009), oral contraceptive use for equal or greater than one year 
duration in patients less than 45 years was associated with a 2.5-fold increased risk of 
TNBC compared to controls 95% CI 1.4 – 4.3 (Dolle et al., 2009). 
Socioeconomic Factors and Poverty: Dunn et al. (2010) reviewed the influence of 
socioeconomic status among different subsets of breast cancers; however, it is clear that 
the effect of socioeconomic factors on TNBC status has not been well studied. Bauer et 
al. (2007) exploring data from the California Cancer Registries found that women with 
TNBC were at higher risk of having a lower socioeconomic status as measured by 
poverty level. Andaya et al. (2012) reported on the disparities in socioeconomic status 
among various breast cancer receptor subsets besides TNBC. They found that high 
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poverty areas tended to have a greater prevalence of one component of TNBC, HR-
negative tumors compared to more affluent areas. This was also observed among young, 
non-Hispanic black women and non-Hispanic Asian/Pacific Islander women with 
regional and distant stage (Andya et al., 2012).  
In a comprehensive review of mortality data Vona-Davis et al. (2009) found that 
social deprivation was associated with poor prognosis in another component of TNBC, 
ER– breast cancer (Vona-Davis & Rose, 2009). While not about TNBC itself, the results 
are illustrative of the influence of social factors on prognosis in breast cancer subsets. 
Environmental Risk Factors: Among 184,418 postmenopausal women aged 50–71 years 
in the National Institutes of Health-AARP Diet and Health Study (1995–2003), Lew et al. 
(2009) performed assessments of multivariate relative risks of alcohol exposure among 
women with various breast cancer receptors, including estrogen receptor-
positive/progesterone receptor-positive, estrogen receptor-positive/progesterone receptor-
negative, and estrogen receptor-negative/progesterone receptor-negative tumors and 
found that the relative risks for breast cancer from alcohol exposure were 1.46 (95% CI: 
1.12, 1.91) for >35 g versus 0 g/day, 1.13 (95% CI: 0.73, 1.77) for >20 g versus 0 g/day, 
and 1.21 (95% CI: 0.79, 1.84) for >20 g versus 0 g/day, respectively.  
On the other hand Kabat et al. (2011) evaluated the association between smoking 
and alcohol intake among TNBC and other subsets of breast cancer (Kabat et al., 2011). 
They found that cigarette smoking was not associated with TNBC, whereas drinkers had 
a reduced risk compared to non-drinkers among TNBC. In contrast, both cigarette 
smoking and alcohol exposures showed slightly positive associations with ER+ breast 
cancer: for women with ≥40 pack-years of smoking, the HR was 1.24, 95% CI 1.06–1.44; 
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for women consuming ≥7 servings of alcohol per week the HR was 1.26, 95% CI 1.06–
1.50. Intakes of spirits such as wine and hard liquor were also significantly positively 
associated with ER+ breast cancer. Li et al. (2010) also found that the risk per drink per 
day of alcohol was statistically significantly lower for ER−PR− breast cancer than it was 
for ER+PR+ breast cancer (multivariable adjusted difference in HRs = 0.74, 95% CI = 
0.58 to 0.93, P = .010) (Li et al, 2010. 
Histological Grades and Stage of Triple-Negative Breast Cancer: TNBC patients tend to 
have breast cancer with higher histologic grades and higher mitotic indices. 
Premenopausal women tend to be at greatest risk of developing TNBC and 39% of 
premenopausal African American women have TNBC (Carey et al., 2006). Breast cancers 
in women with BRCA-1 mutation are more likely to be TNBC (Sorlie et al., 2003). In 
addition, TNBC tend to be diagnosed at a more advanced stage of disease compared to 
controls (OR 2.2, 95% CI 1.0 - 4.9) (Boyle P, 2012). 
 
vii. Triple Negative Breast Cancer Knowledge Gaps and Unmet Needs 
 
Given that the main aim of this study is to evaluate the factors that predict survival in the 
breast cancer phenotype TNBC, the review of the literature indicates that much remains 
unknown about TNBC. While the molecular and clinical correlates of TNBC are still 
being delineated, the epidemiology of TNBC is clearly not well known (Gierach, Burke, 
& Anderson, 2010; Boyle, 2012) and the burden of TNBC in the general population is 
still very unclear (Dolle et al., 2009). Specific, accurate and up to date information from 
58 
 
large population studies on the incidence, prevalence and mortality of TNBC in the US is 
still lacking (Boyle, 2012).  
Knowledge of the age, race, and ethnic group distribution, as well as, other 
demographic and socioeconomic profiles of the TNBC population is still in its infancy 
and is yet to be clearly delineated  (Sturtz et al., 2014); this even though race, BMI and 
other risk factors have been identified in smaller limited studies (Stead et al., 2009). 
Epidemiological correlates such as high BMI have been identified as possible 
independent risk factors for TNBC, especially for African American women (Bauer et al., 
2007; Carey et al., 2006) but methodological issues involving available studies makes 
firm conclusions on the association difficult.  
Oral contraceptive use may also confer an increased risk of developing TNBC as 
opposed to NTNBC (Dolle et al., 2009). Clearly, more work is still to be done regarding 
the identification of major epidemiological determinants of survival in TNBC patients 
(Trivers et al., 2009). Furthermore, apart from the absence of endocrinological 
biomarkers, such as ER, PR and HER2/neu, there are no specific biomarkers that 
distinguish TNBC from NTNBC. Moreover, no other biomarkers have been found to 
correlate with TNBC as yet, although molecular signaling defects have been proposed as 
a differentiating factor (Suba Z, 2014). Early work on the identification of biomarkers for 
the broader basal-like breast cancer subset is in progress (Choo & Nielsen, 2010). Once 
identified, these biomarkers may prove to be useful in the evaluation and treatment of 
patients with TNBC and its correlates (Hudis & Gianni, 2011).  
Until identification and characterization of potential biomarkers are available 
haracterization of risk factors will remain critical in determining who in the general 
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population is at greater risk for developing breast cancer and its subsets, such as TNBC. 
From smaller population studies, the finding that higher rates of TNBC tends to occur 
among selective population groups such as African Americans, Hispanics/Latinos, those 
with high BMI, specific hormonal exposures and lower socioeconomic groups, are 
indicative of the uniqueness of this subset of breast cancer patients that warrant further 
intense and multidisciplinary investigation. 
The uniqueness of this breast cancer subset extends to studying the effectiveness of 
screening for breast cancer with mammography in TNBC perhaps from earlier age groups 
than is recommended for other breast cancer subsets (Amirikia et al., 2011). Effective 
screening and early diagnosis of such patients using mammography are still problematic. 
Preliminary results show that there is some indication that mammography has low rates 
of TNBC detection compared to NTNBC (Bauer et al., 2007; Carey et al., 2006). This 
deserves further study especially if it turns out that the high mortality rates seen in 
African American women with breast cancer is related to the lethal TNBC subset. A 
validated risk model for TBNC has not been developed, as is the case with the Gail 
model for breast cancer and will be useful for individual clinical applications including 
screening. Even effective treatment of TNBC is still in its infancy with many unmet 
needs yet to be fulfilled (Pal, Childs & Pegram, 2011; Hudis & Gianni, 2015). Disparities 
in treatment administered may also help to explain disparities in outcome among TNBC 
compared to NTNBC patients but has not been adequately studied. Studies linking 
socioeconomic factors such as poverty, education level, income level and health 
insurance status to TNBC status, are also lacking in the literature.  
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Helping to confirm specific risk factors for TNBC that may enhance survival in 
these patients will also close a significant knowledge gap that exists and fulfill many 
unmet needs. It is the purpose of this study to help explore and establish the role of 
identifiable determinants of TNBC survival from a large population-database, especially 
among African American women. Knowledge of the impact of TNBC and comparisons 
with NTNBC still remains elusive today, further study of this breast cancer subset may 
help to close the existing knowledge gaps and fulfill a significant unmet need. 
CHAPTER III 
 
METHODS 
 
i. Study Design 
This is a retrospective longitudinal cohort study design, a form of longitudinal 
epidemiologic observational designs, which utilizes the methodologically validated 
Surveillance Epidemiology End Result (SEER) database (Merrill & Capocaccia, 2000). 
 
ii. Population Representative Sample 
The population representative sample for this study was obtained from the SEER 
programs of the National Cancer Institute (SEER - Overview of the SEER Program, 
2015). The data collected includes cancer incidence, prevalence and survival from nine 
population-based cancer registries across the USA since 1973 and are updated annually. 
Data on TNBC became available from 2010 in SEER. The SEER population-base 
currently represents 28 % of the US population and the data collected includes patient 
demographics, primary tumor origin, morphology, stage at diagnosis, course of initial 
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treatment and follow-up data.  The database has a population coverage that includes 26% 
African Americans, 38% Hispanics, 44% American and Alaska Natives, 50% Asians and 
67% of Hawaiian/Pacific Islanders. Comprehensive mortality data are obtained from the 
National Center for Health Statistics and its population data from the US Census Bureau. 
The original 9 registries included Connecticut, Detroit, Hawaii, Iowa, and Utah (1993) 
then Atlanta and Seattle-Puget Sound (1974) were added. These registries expanded in 
2000 to include Greater California, including Los Angeles, Louisiana, New Jersey, New 
Mexico, Utah, Hawaii, Iowa and Kentucky. Specific registries comprise Georgia Center 
for Cancer Statistics that includes Atlanta (1975), rural Georgia (1992) and Greater 
Georgia (2000). California’s Greater Bay Area Cancer Registry includes San Francisco-
Oakland and San Jose-Monterey (1992). Data of indigenous peoples are obtained from 
the Arizona Indians, Cherokee Nation and Alaska Native Tumor Registry (1992).  
Even though rural Georgia and some major rural state registries are included, the 
population represented in the SEER database tends to be more urban than rural and as a 
result has a higher proportion of foreign-born individuals than the general U.S. 
population. Because of its comprehensiveness and stringent validation however, SEER 
data are taken to represent cancer incidence for the entire United States (SEER - 
Overview of the SEER Program SEER, 2015).  
 
                 Table 16: Breast cancer subtypes selected from SEER database. 
 
BREAST SUBTYPE (Data from 2010 - 2012) Frequency Percent 
Her2+/HR+ 17668 1.3 
Her2+/HR- 7889 0.6 
Her2-/HR+ 123437 8.9 
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iii. Procedure 
From the SEER database, 1,385,980 cases of breast cancer from 1973 – 2012 years were 
identified, from which 227,616 breast cancer cases diagnosed between the years 2010 to 
2012 were extracted (See Table 16). The years 2010, 2011 and 2012 are the years for 
which TNBC data are currently available from the SEER database. From these, 168,756 
cases had identifiable breast cancer molecular subtypes, while 58,860 cases of unknown 
breast cancer molecular subtype were excluded from the analysis. The breast cancer 
subtypes were then stratified into five phenotypes: Her2+/HR+, Her2+/HR-, Her2-/HR+ 
and TNBC, where HR was defined as the ER/PR phenotype. Cases with the phenotypes 
Her2+/HR+, Her2+/HR-, Her2-/HR+ were defined as NTNBC and compared with TNBC 
in the analysis.  
 
                        Table 17: Frequency of known breast cancer subtypes. 
Breast Cancer Subtype Frequency Percent 
NTBC 148994 88.29 
TNBC 19762 11.71 
 168756 100.00 
 
Selection Criteria: Female sex, year of diagnosis 2010 – 2012 inclusive, age of diagnosis 
20 – 90 years inclusive, tumor receptors status – (ER, PR, HER2) and data on hormonal 
Triple Negative 19762 1.4 
Unknown 58860 4.2 
Breast Cancer from other years (not 2010 –2012)  1158364 83.6 
Total 1385980 100.0 
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receptors; race (black, white or other); Hispanic/Latino ethnicity, marital status, tumor 
grade at diagnosis, treatment, insurance status and recorded survival time > 1 month 
using SEER cause of death code. 
Exclusion criteria: Males, missing values, death from other causes other than having the 
breast cancer cause of death code (treated as censoring in the analysis) were excluded. 
Predictor Variables: Age, race (Black or White), ethnicity (Latino/Hispanic, non-
Hispanic), marital status, health insurance status, histological tumor grade, and treatment 
were the regression independent variables. It was found that there were nineteen SEER 
geographic variables which made inclusion into the Cox models complex, hence 
geographic localities were excluded in the model.  
Outcome Variables: Breast cancer survival was the dependent or outcome variable.  
 
iv. Statistical Analysis 
The study aim is to evaluate the association between breast cancer phenotypes and 
specific predictor variables in a large sample of female breast cancer patients. Means ± 
SD, frequencies and associated percentages of continuous demographic variables among 
TNBC and NTNBC cases were subjected to z-testing. Categorical variables were 
assessed using Chi-Square tests.   
Using SPSS software version 21 (SPSS Inc., Chicago, Illinois) Cox proportional 
hazard models evaluated factors predicting survival time (outcome variable) among 
TNBC and NTNBC. The Cox hazard model is a semiparametric, in contrast to the 
alternative Kaplan-Meier non-parametric, survival method, that can evaluate multiple 
variables simultaneously. Predictor variables in the model were age categories, age at first 
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diagnosis, race, ethnicity, marital status, grade, surgery, radiation, and insurance status 
and were also subjected to logistic regression analysis to examine predictors of receiving 
or not receiving standard treatment.  
The model for the effect on TNBC of the predictor variables and repeating the 
process for the effect on NTNBC alone of the other predictive variables were run 
separately. The results of the stratified analysis were presented in a combined table for 
ease of reading. For the analytical models, categories with fewer cases were combined, in 
particular - the combination of American Indian/Alaska Native, and Asian/Pacific 
Islander as “Other” Races. 
The Cox survival results are summarized as the hazard ratio (HR) with associated 
95% confidence interval (CI) with two sided tests of significance (p ⩽ 0.05). 
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CHAPTER IV 
 
RESULTS 
 
The main aim of this study was to close the epidemiological gaps and evaluate the factors 
that predict survival in the breast cancer phenotype TNBC. In this study, the proportion of 
TNBC among breast cancer subsets is 11.71 %. For African Americans the proportion is 
21.6% compared to 10.8% in whites. Some of the other patient characteristics and 
demographic information determined in this study are as follows:  
 
i. Demographics and Patient Characteristics 
Age: Table 18 shows the age distribution of cases in the data set. TNBC cases were 
younger (mean age 58.67 ± 13.57 years) than NTNBC cases (mean age 61.51 ± 13.57 
years). Among TNBC cases 8.4% are less than 40 years old while 4.5% of NTNBC cases 
are less than 40 years old a disparity of 4% point. Similarly 53.6% of TNBC cases are 59 
years or less compared to 44.7% of NTNBC cases a disparity of 9% point.   
The peak proportion of TNBC (20.01%) occurs in the < 40 age group while in 
NTNBC the peak proportion (90.45%) occurs in the 70 – 79 age group again 
demonstrating that TNBC is a disease of younger women than is the case for NTNBC. 
The difference in mean age at diagnosis between NTNBC and TNBC cases was 2.843 
years, (95% CI: 2.623, 3.063), p < 0.0001.  
Table 19 shows other demographic variables among the study population including: 
Race/Ethnicity: A greater proportion of TNBC cases are African American (21.55%)) 
than white women (10.84%), a disparity difference in frequency of 10.71% (p < 0.001). 
However, at p = 0.05 level of significance, for frequency of TNBC among Hispanic 
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(13.13%) and non-Hispanic (11.76%) ethnicity, the difference was not statistically 
significant p = 0.07. 
 
            Table 18: Frequencies of age categories for TNBC and NTNBC. 
 
Age Categories NTNBC TNBC Total P-value 
< 40 years 5976 (79.99%) 
(4.5) 
1495 (20.01%) 
(8.4) 
7471 < 0.001 
40-49 years 21172 (86.19%) 
(16.1) 
3391 (13.81%) 
(19.1) 
24563 < 0.001 
50-59 years 31701 (87.22%) 
(24.1) 
4645 (12.78%) 
(26.1) 
36346 < 0.001 
60-69 years 35247 (89.34%) 
(26.8) 
4205 (10.66%) 
(23.7) 
39452 < 0.001 
70-79 years 23344 (90.45%) 
(17.8) 
2466 (9.55%) 
(13.9) 
25810 < 0.001 
≥80 years  14068 (90.01%) 
(10.7) 
1561 (9.99%) 
(8.8) 
15629 < 0.001 
Total 131508 
(100.0)  
17763 
(100.0)  
149271  
Mean Age (S.D) 61.51 (13.57) 58.67 (14.11)   
Values in red and parenthesis are relative percentages within columns 
Values in black and parentheses are relative percentages within rows 
 
Other Races: The proportion of “other” women with TNBC was 9.75% while for white 
women it was 10.84 which was statistically significant difference at p = 0.05 level. 
Similarly, compared to African American women (21.55%), TNBC in the “other” racial 
group, defined as the combination of American Indian/Alaska Native, and Asian/Pacific 
Islander, was smaller, a difference that was statistically significant.  The findings show 
that 19.8% of TNBC cases compared to 9.8% of NTNBC are of African American cases, 
a disparity difference of 10.0%. However, among Hispanics there is no difference 
between NTNBC (10.4%) and TNBC (11.7%) cases.  
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Marital Status: The proportion of TNBC among married women (11.55%) was not 
different statistically from that of unmarried women (12.37%).  
There was no disparity in frequencies based on marital status (Table 19). 
 
                     Table 19: Frequencies of other demographic variables. 
 
 NTNBC TNBC Total N P-value 
N 131508 17763 149271  
     
Mean Age at 
Diagnosis (S.D)  
61.51 (13.57) 58.67 (14.11) 149271 < 0.001 
     
Race     
          White 106155 (89.16%) 
(81.3) 
12910 (10.84%) 
(73.1) 
119065 < 0.001 
          Black 12727 (78.44%) 
(9.8) 
3497 (21.55%) 
(19.8) 
16224 < 0.001 
          Other 11617 (90.25%) 
(8.9) 
1255 (9.75%) 
(7.1) 
12872 < 0.001 
     
Ethnicity     
       Non-Hispanic  117800 (88.24%) 
(89.6) 
15692 (11.76%) 
(88.3) 
133492 <0.001 
       Hispanic 13714 (86.87%) 
(10.4) 
2072 (13.13%) 
(11.7) 
15786 < 0.070 
     
Marital Status     
       Unmarried 52692 (87.63%) 
(54.2) 
7437 (12.37%) 
(52.4) 
60129 < 0.001 
       Married 71330 (88.45%) 
(45.8) 
9317 (11.55) 
(47.6) 
80647  0.001 
     
Other = American Indian/Alaska Native, Asian/Pacific Islander 
Values in red and parenthesis are relative percentages within columns 
Values in black and parentheses are relative percentages within rows 
 
 
Tumor Grade: For tumor histological grade at the time of diagnosis, the peak prevalence 
of TNBC was for Grade IV (31.91%) with Grade III (28.28%) a close second. For 
NTNBC the peak prevalence occurred at Grade I (98.83%) and Grade II (95.21) a close 
68 
 
second. This indicates that a greater proportion of women with TNBC have higher 
histological tumor grades (IV and III) at the time of diagnosis than women with NTNBC 
(grades I and II) and frequency of tumor histological grade disparity (Table 20).  
 
         Table 20: Frequencies of clinical variables: grades, treatment, insurance status.  
 
Clinical NTNBC TNBC P-value 
Tumor Grades     
      Grade I 31719 (98.83%) 
(25.3) 
376 (1.17%) 
(2.2) 
< 0.001 
      Grade II 59215 (95.21%) 
(47.3) 
2981 (4.79%) 
(17.7) 
< 0.001 
      Grade III 33807 (71.72%) 
(27.0) 
13330 (28.28%) 
(79.0) 
< 0.001 
      Grade IV 414 (68.09%) 
(0.3) 
194 (31.91%) 
(1.1) 
< 0.001 
    
Surgical Status    
      Performed 121095 (88.25%) 
(92.8) 
16129 (11.75%) 
(91.8) 
< 0.001 
      Not performed 9462 (86.81%) 
(7.2) 
1438 (13.19%) 
(8.2) 
< 0.001 
    
Radiation    
      Performed 63767 (88.87%) 
(50.5) 
7986 (11.13%) 
(47.4) 
< 0.001 
      Not Performed 62414 (87.59%) 
(49.5) 
8846 (12.41%) 
(52.6) 
< 0.001 
    
Insurance Status    
     Uninsured 2294 (83.42%) 
(1.8) 
456 (16.58%) 
(2.6) 
< 0.001 
     Insured  125406 (88.08%) 
(98.2) 
16970 (11.92%) 
(97.4) 
< 0.001 
Values in red and parenthesis are relative percentages within columns 
Values in black and parentheses are relative percentages within rows. 
 
Insurance Status: For insurance status a statistically significant but smaller percentage of 
women with TNBC were insured (11.92%) than uninsured (16.56%) (Table 20). 
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Tables 18, 19 and 20 all show comparative frequencies for TNBC and NTNBC status 
together with certain specific variables with p-values for test of significant differences of 
proportions within and between TNBC and NTNBC substes. 
 
ii. Survival Analysis Results 
 
The mean survival time for TNBC is statistically less than that for NTNBC (Table 21). 
The overall mean survival time (± S.D.) for TNBC is 15.60 (± 10.29) months compared 
to 16.01 (± 10.18) with a mean disparity difference of 0.410 months (95% CI: 0.251, 
0.570, p < 0.0001).  
Cox Regression Analysis: The results of the overall model in the Cox regression analysis 
are shown in Table 22. The model yields an equation for the hazard as a function of 
predicted variables. This multivariate Cox proportional hazards model for various factors 
found that in TNBC patients, young age at diagnosis, African American race, unmarried 
status, high tumor grade, lack of treatment (surgery and radiation), as well as, uninsured 
status all had significantly higher hazard rates of death and poorer outcome than NTNBC 
patients. Among race/ethnicity groupings, white race, Hispanic origin and “Other” races 
defined as American Indian/Alaska Native, Asian/Pacific Islander, compared to African 
American women had comparatively lower hazard rates of death and higher survival. A 
Cox model that compares separately TNBC with NTNBC as a function of the predictive 
variables will be reported in Table 25. That model was generated by analyzing survival in 
TNBC alone (without NTNBC) with respect to other predictive variables. Another model 
was generated from the same sample population by analyzing NTNBC without TNBC 
with respect to other predictive variables and reported in the same Table 25.  
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Molecular Subtype: With NTNBC as the reference, the Cox regression model 
demonstrated that overall breast cancer survival is significantly less for the TNBC subset 
of patients. In that analysis, estimated hazard or risk of death for a TNBC woman 
increases 2.285 times that of a NTNBC patient and is a statistically significant difference 
in survival (hazard ratio 2.285, 95% CI: 2.144, 2.434).  
Age: Regarding age at diagnosis, the estimated risk of death increases by 1.033 times and 
is a statistically significant difference, hazard ratio = 1.033, (95% CI 1.033, 1.041). 
Compared to a woman > 80 years old, a woman < 40 years old has a 1.211 times higher 
risk of death, hazard ratio = 1.211, (95% CI: 0.759, 1.688), which achieved statistical 
significance. 
Race: With white women as reference, the estimated risk of death for an African 
American increases 1.2 times that of a white woman. This increase although small had a 
95% CI (1.117, 1.289) that did not include 1 and achieved statistical significance.   
Marital Status: With a married woman as reference, an unmarried woman with TNBC the 
estimated risk of death decreases 0.697 times that of a married woman which was 
statistical significant. Unmarried status seemingly conferring a protective status for risk 
of death in women compared to married women.    
Histological Grade: For a woman who had higher histological grade tumor (grade IV), 
her estimated risk of death was 2.81 times higher than that of a woman who had a lower 
grade tumor (Grade I), a difference that was statistically significant (hazard ratio 2.812, 
95% CI: 2.159, 3.661).                                                                                                  
Health Insurance: For an uninsured woman, the estimated hazard or risk of death  
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increased 1.717 times that of a woman with health insurance which is a statistically 
significant difference in survival (hazard ratio = 1.717, 95% CI: 1.481, 1.992). 
 
Treatment Status: The results for surgery indicates that for a woman who did not have 
surgery for whatever reason, had an estimated 8.633 times higher risk of death than a 
woman who had surgery. The beta coefficient for this relationship is a positive value 
indicating that the hazard is increased or survival is decreased.  
 
                                  Table 21: Survival Time for NTBC and TNBC. 
 
 Survival time (months) 
 NTNBC TNBC Mean 
Difference 
95% CI of 
Mean 
Difference 
p-value 
N 131514 17764    
Mean 
(S.D) 
16.01(10.291) 15.60 (10.187)    
   0.410 0.251, 0.570 <0.0001 
 
 
This decrease in survival is statistically significant, p ≤ 0.001 (hazard ratio = 8.633, 95% 
CI: 8.152, 9.143). Similarly, but to a lesser extent, for radiation treatment, a woman with 
breast cancer who did not have radiation therapy had an estimated 2.285 higher hazard or 
risk of death than a woman who had radiation therapy. This finding of lower survival 
among women with breast cancer not receiving/ receiving radiation was a statistically 
significant difference in survival, p ≤ 0.001 (hazard ratio = 2.285, 95% CI: 1.535, 1.732). 
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The results of this complete model with all independent variables and the survival 
outcome variable are shown in Table 22. The tabulation includes values of the β 
coefficient, hazard ratios with associated 95% confidence intervals and p-values. 
                      Table 22: Cox regression survival analysis of variables. 
 
         Variables β p-value Hazard  Ratio              95% CI  
 
Histological 
Grade 
    
   Grade I Reference.    
   Grade II 0.326 < 0.0001 1.385 1.271, 1.508 
   Grade III 0.887 < 0.0001 2.428 2.228, 2.646 
   Grade IV 1.034 < 0.0001 2.812 2.159,3 .661 
     
Age (Years)     
    ≥80 Reference    
   < 40 0.124 0.543 1.132 0.759, 1.688 
   40 - 49 -0.170 0.287 0.844 0.617, 1.153 
   50 - 59 -0.251 0.041 0.778 0.612, 0.990 
   60 - 69 -0.262 0.003 0.769 0.647, 0.915 
   70 -79 -0.165 0.004 0.848 0.759, 0.948 
     
Treatment Reference    
   No Surgery 2.156 < 0.0001 8.633 8.152, 9.143 
   No Radiation 0.489 < 0.0001 1.630 1.535, 1.732 
     
Subtypes     
   NTNBC Reference    
   TNBC 0.826 < 0.0001 2.285 2.144, 2.434 
     
Age at 
Diagnosis 
0.033 < 0.0001 1.033 1.026, 1.041 
     
Ethnicity     
   Non-Hispanic Reference    
   Hispanic -0.064 0.169 0.938 0.855, 1.028 
     
Race     
   White Reference    
   Black 0.182 < 0.0001 1.200 1.117, 1.289 
   Other -0.300 < 0.0001 0.741 0.661, 0.830 
     
Insurance Status     
   Insurance Reference    
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   No Insurance 0.541 < 0.0001 1.717 1.481, 1.992 
     
Marital Status     
   Married Reference    
   Unmarried -0.362 < 0.0001 0.697 0.658, 0.737 
 
    Figure 6: Survival curve function by breast cancer subtypes (TNBC and NTNBC). 
                                   Legend: NTNBC (blue), TNBC (red) 
 
The Cox regression results in Table 22 show that there are significant disparities in 
survival for various outcome variables, with statistically lower survival for 
TNBC than NTNBC status, higher histological tumor grades (Grades III and IV), lower 
age at diagnosis, chronological age for the age groups ≥ 50 years up to > 79 years 
(compared to the reference age > 80 years), married women, African American race, 
uninsured status, and no treatment administered for both surgical and radiation treatment. 
The survival curve (Figure 6) illustrates the change in cumulative survival on the y-axis 
versus time in months in the x-axis. This survival function curve is generated from a 
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comparison of the survival function for both TNBC (red) and NTNBC (blue) over time, 
and illustrates the survival differences of both subsets diverging over time up to the limit 
of the 36 month duration of the study.  
Table 23: Logistic regression analysis for no surgery vs. surgery and other variables. 
 
     
Variables β p-Value Odds Ratio 95% CI 
Age Categories     
   < 40 years Reference    
   40-49 years -0.921 < 0.0001 .398 0.352, 0.450 
   50-59 years -1.223 < 0.0001 .294 0.251, 0.345 
   60-69 years -1.734 < 0.0001 0.177 0.143, 0.218 
   70-79 years -2.050 < 0.0001 0.129 0.098, 0.169 
   ≥80 years -1.660 < 0.0001 0.190 0.136, 0.266 
     
Receptor Status     
   NTNBC Reference    
   TNBC 0.102 0.001 1.107 1.042, 1.177 
     
Hispanic Origin     
   Non- Hispanic Reference    
   Hispanic 0.174 < 0.0001 1.190 1.112, 1.273 
     
Race     
   White Reference    
   Black 0.590 < 0.0001 1.804 1.702, 1.912 
   Other 0.019 0.637 1.019 0.942, 1.103 
     
Age at Diagnosis 0.051 < 0.0001 1.053 1.046, 1.059 
     
Insurance Status     
   Insured Reference    
   Uninsured 1.268 < 0.0001 3.552 3.206, 3.937 
Constant 4.508 < 0.0001 .011  
 
 
 
A statistically significant difference in survival time for TNBC and NTNBC patients was 
reported previously. With NTNBC as the reference, the Cox regression model also 
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demonstrated that overall breast cancer survival is significantly less for the TNBC subset 
of patients. The estimated hazard or risk of death for a TNBC woman increases 2.285 
times that of a NTNBC patient (hazard ratio 2.285, 95% CI: 2.144, 2.434).  
Table 24: Logistic regression analysis for radiation vs no radiation and other variables. 
 
Variables β p-value Odds Ratio 95% CI 
Age category     
   < 40 years Reference    
   40-49 years -0.329 < 0.0001 0.720 0.674, 0.769 
   50-59 years -0.710 < 0.0001 0.492 0.450, 0.537 
   60-69 years -0.987 < 0.0001 0.373 0.331, 0.419 
   70-79 years -0.840 < 0.0001 0.432 0.372, 0.501 
   ≥80 years  -0.218 < 0.023 0.805 0.667, 0.970 
     
Status     
   NTNBC Reference    
   TNBC 0.140 <0.0001 1.151 1.113, 1.190 
     
Hispanic origin     
   Non- Hispanic Reference    
   Hispanic 0.229 < 0.0001 1.258 1.214, 1.303 
     
Race     
   White     
   Black 0.122 < 0.0001 1.130 1.091, 1.170 
   Other 0.164 < 0.0001 1.179 1.134, 1.225 
     
Age at diagnosis 0.020 < 0.0001 1.020 1.017, 1.024 
     
Insurance status     
   Insured     
   Uninsured 0.276 < 0.0001 1.318 1.217, 1.429 
Constant -0.682 < 0.0001 0.505  
 
The logistic regression analysis modeling “no surgery” results in Table 23 and “no 
radiation” in Table 24 showed that TNBC, African American, uninsured,  are less likely 
to receive surgery or radiation treatment. For TNBC it was 10%, African American 80% 
and uninsured 355% less likely to get surgery. While for radiation, it was 15% (TNBC), 
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13% (African American) and (uninsured) 31.8% less likely to receive radiation. So for 
the dichotomous treatment variables, comprising the binary outcomes of surgery/no 
surgery and radiation/no radiation indicate a significant treatment effect for both ‘no 
surgery’ and ‘no radiation’ versus surgery and radiation respectively, and predictive 
variables age at diagnosis, African American race, uninsured status and TNBC versus 
NTNBC.  
The overall Cox model previously described under Survival Analysis Results 
provided information on all the variables acting in concert. To separately assess the 
model for the effect of TNBC alone on the other variables and repeating the process for 
the effect of NTNBC alone on the other variables, the model was executed with TNBC 
and the other variables but without NTNBC and the results reported. It was again 
executed, this time with NTNBC and the other variables but without TNBC and the 
results reported. 
The results are shown in Table 25 and the resulting survival curves shown in 
Figure 6 and Figure 7. This modified split models show that for the variable race, African 
American, white and the “other” racial groups, there is a statistically significant 
difference in survival for each of TNBC and NTNBC subsets when the model was 
executed separately. The survival findings that distinguish various racial groups will be 
described in the next section. 
Race: The estimated hazard or risk of death for the combined “other” racial groups show 
a decreased risk of death for patients with both TNBC and NTNBC when compared to 
both African American and white races. For African American women with TNBC, risk 
of death was 1.219 times that of white women with TNBC. In African American women 
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with NTNBC, the risk of death was 1.341 times that of a white woman with NTNBC. 
Results were statistically significant for both TNBC and NTNBC. In this divided model, 
for an African American woman with TNBC when compared to a white woman with 
TNBC, the difference in survival did achieve statistical significance (p = 0.001) as was 
the case for NTNBC where the survival difference also achieve statistical significance 
(hazard ratio = 1.341 95% CI: 1.234, 1.458, p < 0.0001).  
Age at diagnosis: Another variables that achieved statistical significance for this divided 
model was age at diagnosis (hazard ratio = 1.033, 95% CI: 1.026, 1.041, p < 0.0001).  
Treatment status: For the treatment status of patients who had no surgical treatment 
compared to those who had surgical treatment, the survival difference achieved statistical 
significance, with those not receiving surgery having a lower survival (hazard ratio = 
8.633, 95% CI: 8.152, 9.143, p < 0.0001). A woman who did not have surgery had 8.633 
times increased risk of death than a woman who had surgery. Those who had no radiation 
treatment had a statistically lower survival compared to those who had radiation 
treatment (hazard ratio = 1.630, 95% CI: 1.535, 1.732, p < 0.0001). A woman who had no 
radiation treatment had 1.630 times increased risk of death than a woman who had 
radiation treatment a difference that was statistically significant. 
Tumor grade:  Patients who had higher tumor histological grades (Grade II, III and IV 
compared to Grade I) tended to have lower survival than those who had a lower tumor 
grade. In fact the analysis demonstrated a gradient in decreased survival going from 
lower grade to higher grade, with the worst survival progressing from Grade II to Grade 
IV, all differences being statistically significant (Grade II, hazard ratio = 1.385, 95% CI: 
1.271, 1.508, p < 0.0001), (Grade III, hazard ratio = 2.428, 95% CI: 2.228, 2.646, p < 
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0.0001), (Grade IV, hazard ratio = 2.812, 95% CI: 2.159, 3.661, p < 0.0001). In this 
schema a woman who had Grade IV had 3.661 times higher risk of death than a woman 
who had a Grade I tumor, which was a statistically significant difference in survival. 
                    Table 25: Cox proportional hazard results TNBC and NTNBC. 
 
  
                          TNBC                       NTNBC 
Variable  β Hazard Ratio 
(95% CI) 
p-value β Hazard Ratio 
(95% CI) 
p-value 
Age at 
Diagnosis 
0.036 1.037 
(1.022,1052) 
<0.0001 0.034 1.033 
(1.024, 1.041) 
< 0.0001 
       
Race       
  White  Reference   Reference  
  Black 0.198         1.219 
(1.066,1.369) 
0.001 0.293 1.341 
(1.145, 1.367) 
< 0.0001 
  Other -0.377 0.686 
(0.550, 0.856) 
0.003 -0.289 0.753 
(0.660, 0.859) 
< 0.0001 
       
Ethnicity       
  Non-Hispanic  Reference   Reference  
  Hispanic -0.057 0.945 
(0.803, 1.111) 
0.272 -0.050 0.949 
(0.850, 1.058) 
    0.349 
       
Treatment 
Status 
      
  Surgery  Reference   Reference  
  No Surgery 2.208 9.094 
(8.148, 10.149) 
<0.0001 2.157 8.647 
(8.116, 9.214) 
< 0.0001 
  Radiation  Reference   Reference  
  No Radiation 0.280 1.323 
(1.191, 1.471) 
<0.0001 0.582 1.790 
(1.668, 1.920) 
< 0.0001 
Grade       
  Grade I  Reference   Reference  
  Grade II 0.680 1.974 
(1.265, 3.075) 
    0.003 0.283 1.347 
(1.234, 1.470) 
< 0.0001 
  Grade III 0.979 2.662 
(1.728, 4.102) 
< 0.0001 0.917 2.515 
(2.301, 2.749) 
< 0.0001 
  Grade IV 1.299 3.666 
(2.109, 6.372) 
< 0.0001 1.091 2.802 
(1.984, 3.957) 
< 0.0001 
       
Age 
 
      
  < 40 year  Reference   Reference  
       
  40 – 49 0.384 1.099 
(0.585, 2.067) 
0.769 -0.207 0.813 
(0.641, 1.031) 
0.087 
  50 – 59 -0.686 0.843 0.493 -0.154 0.857 0.219 
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(0.517, 1.374) (0.660, 1.114) 
  60 – 69 -0.863 0.731 
(0.514, 1.040) 
0.082 -0.149 0.862 
(0.631, 1.176) 
0.348 
  70 - 79 -0.852 0.755 
(0.599, 0.952) 
0.18 -0.033 0.997 
(0.686, 1.449) 
0.988 
  ≥ 80 -..489 0.613 
(0.285,1.323) 
 0.172 1.188 
(0.756,1.867) 
0.456 
 
iii. Survival Curves 
 
Figures 6, 7 and 8 are all survival curves that illustrate the plot of cumulative survival 
versus survival time for the two breast cancer subsets, TNBC and NTNBC.  
Figure 6 is a survival plot for the overall model that shows statistically significant 
survival differences among TNBC and NTNBC.  
                    
Figure 7: Survival function curves for TNBC and race. 
  These 
results illustrates the findings that the data satisfies the second hypothesis of this 
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dissertation outlined previously. Figure 7 illustrates the significant differences in survival 
for female racial groups, white, African American and “other” among for TNBC. While 
Figure 8 shows similar differences in survival for the same racial groups among NTNBC 
patients.  The findings satisfy the first hypothesis posited previously in this dissertation 
regarding survival among racial groups. This hypothesis states that survival is lower in 
African American patients compared with Non-Hispanic white women among TNBC 
patients.  The results shown in Table 25 confirms this main hypothesis of this study and is 
illustrated in Table 6 that there is a statistically significant difference in survival between 
white women and African American women with TNBC. 
 
                   Figure 8: Survival function curves for NTNBC and race. 
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CHAPTER V 
 
DISCUSSION 
 
i. Discussion 
The main goal of this study was to help close the epidemiological knowledge gaps 
regarding TNBC. In this direction, this large population study found that TNBC 
represented 11.71% of all molecular subsets of breast cancer compared to 88.29% of 
NTNBC subset. This 11.71% is at the lower end of the range of estimates found in the 
limited available literature on TNBC. This estimate is probably close to the actual 
estimate in the general population since the SEER population is closely representative of 
the general population. Despite this relatively small frequency, the epidemiological 
analysis of this subset, yield results which help to explain significant prognostically 
unfavorable aspects of breast cancer overall.  
The TNBC intrinsic and extrinsic determinants (factors which broadly determine 
the frequency and impact of disease in the population) that were examined in this study 
include, age , race, ethnicity, marital status, health insurance status, histological tumor 
grade, and treatment received or not received, all have been shown to impact survival to 
varying extents in patients with breast cancer. A geographic-locality variable was 
excluded in the analysis because of the complex number of variables associated with it in 
the SEER database. The results, however, demonstrate a number of disparities that 
hitherto, were not definitively established in studies of this size, and in some instances 
were previously unknown prior to this undertaking:  
Determinants and Disparities: This study has clearly demonstrated that age at diagnosis 
is a significant determinant of survival in TNBC patients. For categories of age, younger 
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age is significantly less in TNBC versus NTNBC patients. The results also show that 
there is a significant disparity and higher hazard rate in survival regarding age at 
diagnosis. The survival data showed that TNBC patients, less than age 40 years have 
12.4% lower survival rate as compared to women older than age 80 years. This is 
indicative of the lethality of TNBC in younger women such that octogenarians have 
12.4% better survival than younger, premenopausal women with the disease subset. The 
lower survival age-disparity among TNBC compared to NTNBC has not been previously 
demonstrated in any studies of this population size. While the disparity in age has been 
implicated in other smaller studies, with age and specifically younger age as a risk factor 
for TNBC (Dent et al, 2007; Dolle et al., 2009, Bauer et al., 2007), this is the first study 
of this size and design to demonstrate the magnitude of this adverse survival effect.  
Why the disparity in age and survival among TNBC populations? This is a subject 
of great speculation. Clearly, biological (especially genetics), environmental and social 
factors may play a role. One previous study offered the intriguing prospect in answer to 
this question, in the example of oral contraceptive use. Dolle et al. 2009, previously 
demonstrated an increased risk of oral contraceptive use among TNBC compared to 
controls in women, at or less than 40 years old (Dolle et al., 2009).  
However, correlation does not imply causation. Moreover, the latency between 
carcinogenic exposure and cancer development is probably in the magnitude of many 
years (Clapp et al., 2008), so other putative factors may better explain the younger age 
predilection for TNBC than NTNBC and will have to be explored in other studies. Not 
surprisingly, this study revealed that race was a determinant of survival and significant 
disparities in race and survival among both TNBC and NTNBC exists. In terms of 
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frequencies among the breast cancer subsets, less white women (over 8% point) had 
TNBC than NTNBC while twice as many African American women had TNBC than 
NTNBC. The survival data confirmed the expected poorer survival among African 
American than white women with TNBC. The estimated hazard or risk of death for an 
African American woman with TNBC increases 34 % that of a white woman with TNBC. 
Even the combined “Other” races had a 30% decreased risk of death after the adjustment 
for the same variables in the model.  
The study also showed that histological tumor grade was a determinant of survival 
in TNBC but the gradient with Grade III exhibiting greater disparity compared to survival 
in Grade I and II was quite surprising. What was also surprising were the frequencies of 
the tumor grades observed in this study with 79% of TNBC patients having grade II 
while only 27% of NTNBC patients had grade II. 25.3 % of NTNBC patients had grade I 
while only 2.2% of TNBC patients.  The findings indicate that a greater proportion of 
TNBC patients tend to have a poorly differentiated breast cancer cellular profile at the 
time of diagnosis while fewer NTNBC do.  
This goes to the observed greater lethality of this subset at the time of diagnosis 
and the resulting poorer survival seen in TNBC patients overall. It speaks to biology as a 
major contributor to the disparity seen in the mortality between TNBC and NTNBC 
patients.  Disparities in those receiving surgical and radiation treatment were observed 
among African American, uninsured, and TNBC patients compared to white, insured and 
NTNBC patients. This treatment disparity may in part explain the poor survival seen in 
TNBC patients, although poorer survival in TNBC is likely due to other factors as well. 
While this study does shed light, not only on the determinants of survival, but also 
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possible answers as to why these determinants may be causally related to the poor 
survival in TNBC and NTNBC. Future studies using other designs will be needed to 
further elucidate causation.  
Still, the presence or absence of quality treatment is expected to independently 
predict survival in breast cancer (Odle, 2014).  Disparities in quality of treatment have 
been shown to adversely affect survival in other health conditions (Bradley, Given & 
Roberts, 2002). Surgical and radiation treatments, while part of standard treatment for 
breast cancer, are probably not by themselves the most effective treatment modalities for 
TNBC. Currently, the addition of systemic chemotherapy to surgery and locoregional 
radiation therapy should be a major part of the standard armamentarium against TNBC. 
While this may change in the future as a result of more effective treatment modalities 
such as biological therapy, the available forms of treatment today are not as effective for 
treating TNBC as it is for NTNBC. This also goes to the possible intrinsic biological 
aggressiveness and resistance to current forms of treatment for TNBC as opposed to 
NTNBC.  
This study did not evaluate the merits of one form of treatment versus another in 
TNBC. That would be the remit of clinical trials. Its focus was on treatment in currently 
available forms, as a possible determinant of survival in the various subsets of breast 
cancer under study here.  
Health insurance was also shown to be a significant determinant of survival in TNBC. 
As an index of socioeconomic status, health insurance status has hitherto been one 
explanation for poorer prognosis and survival in a number of health conditions. It has 
been shown previously in selected patient populations that quality of care or lack thereof 
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is linked to the availability or non-availability of health insurance (Lillie-Blanton & 
Hoffman, 2005). In a changing social environment during the years of this study, 2010 -
2012, fewer and fewer patients were without health insurance, so this factor was expected 
to play a smaller role in predicting survival in breast cancer subsets.  
A small but statistically significant disparity difference in frequency of 0.8 % was 
observed among the uninsured for TNBC (2.6%) and NTNBC (1.8%). The disparity of 
TNBC survival seen in this study among those with and without health insurance is a new 
finding and not previously reported. In the Cox model, the estimated hazard or risk of 
death for a patient without health insurance and TNBC increases 1.72 times that of an 
insured patient which is a statistically significant difference in survival. This and other 
such findings help confirm the study hypotheses that there are specific determinants and 
disparities in survival among TNBC and NTNBC patients. 
 
ii. Limitations 
One major limitation of this study is that some factors affecting survival remain ill-
defined or unknown and consequently are not reflected in this dissertation or some 
current database registries. TNBC is only one of many yet unknown breast cancer subsets 
contributing to current breast cancer mortality and its impact on survival is still to be 
determined.  Another limitation is that databases themselves are limited in scope and the 
availability of a large menu of study variables that may affect outcome is still few and not 
well quantifiable. In particular, a complete menu of treatment modalities currently 
administered to patients with breast cancer that would help to better explain survival-
treatment disparities between TNBC and NTNBC is lacking. 
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iii. Implications 
 
These findings may have implications for policy changes that may refocus emphasis and 
priorities regarding screening, treatment and research on breast cancer subsets in African 
American women. Further studies focused on African American women may alter and 
direct mammographic screening guidelines specifically for this racial group, and 
especially towards younger age groups, such that current screening guidelines may have 
to be modified for African American women to better detect breast cancer at an earlier 
age, stage and grade. Earlier detection in this younger age group in particular may alter 
the current dismal mortality trajectory. As a result of this early screening intervention, 
African American women, if treated earlier in the course of their disease, may have a 
better long-term prognosis than currently exists.  
Earlier treatment for at-risk populations as a result of earlier screening may be 
developed given the disparity data found here. For instance, new chemotherapy and 
biological therapies specific to TNBC patients may be tailored to this at-risk population 
with resultant improvement in efficacy – more equitable treatment approaches for all 
racial groups may thus lead to decreases in mortality for breast cancer in general and 
TNBC in particular, especially among African American women.  
These findings could signal a new impetus do more frequent molecular typing in 
this at risk population subset. While not evaluated in this study, but on the basis of other 
study results, perhaps BRCA mutational studies can also be targeted for screening in this 
at-risk population. Undoubtedly, large methodologically sound studies will needed to 
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better evaluate the impact of BRCA mutation and other as yet unknown biological 
markers for screening in this at-risk group. 
These findings may also have implications for genetic research and the 
development of biomarkers specific for TNBC and especially among women of African 
American ancestry.   
 The findings might also provide the momentum to develop treatment modalities 
that de-emphasizes endocrinological measures in this racial group and instead emphasizes 
systemic therapy to a greater extent. For instance, new chemotherapy and biological 
therapies specific to TNBC patients may be tailored to this at-risk population with the 
resultant improved efficacy and outcomes.  
The implications of socioeconomic factors and their impact on TNBC incidence, 
treatment, and mortality in the population, may gather greater thrust for study and action 
based on the present findings. While insurance status is only one indicator of 
socioeconomic status in the population, other studies using other indicators, such as 
income, education, housing, etc. should be undertaken with respect to TNBC outcomes 
and disparities, so as to better explain the impact of socioeconomic status on this subset 
in the population that may alter its prognostic trajectory. 
 The present findings have established that the higher histologic grade at 
diagnosis, and by implication the more aggressive and lethal nature of TNBC, have 
implications for cell receptor biology and identifies the need for further work to be 
undertaken regarding unique biological parameters operating in this population subset.    
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Finally, the present findings has implications for primary and secondary 
prevention research. More population studies inclusive of minority women needs to be 
undertaken, specifically with regards to prevention strategies in at-risk groups. 
CHAPTER VI 
 
RECOMMENDATIONS AND CONCLUSION  
      
i. Recommendations 
 
This is the first large scale population study to demonstrate that, despite the small 
proportion of the population affected by this breast cancer subset, TNBC has a 
disproportionally larger impact on the survival rates of African American women than 
white women or women of “other” races in the United States. The lack of proven 
effective treatment modalities and the poorer survival outcome reported in this study 
makes TNBC a significant disease entity requiring substantially greater and concerted 
measures, involving the primary and secondary prevention of breast cancer, to be 
implemented in this population. 
For this, it is recommended that among the substantive preemptive measures for 
curbing this lethal condition are primary prevention against known and unknown 
environmental and carcinogenic exposures including alcohol abuse and radiation 
exposure; increasing educational and behavior modification measures directed towards 
obesity reduction, with tailored diet and exercise programs; implementation of modifiable 
reproductive risk reduction measures, including endogenous endocrine interventions 
directed at altering timing of menarche, menopause, age at first birth and breast feeding 
choices. 
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Intensification of research efforts on newer genetic screening procedures that are 
effective for detecting TNBC and other subsets and the utilization of innovative genomic 
techniques in the assessment of women at-risk for breast cancer subtypes are also 
strongly recommended in this public health policy schema.  
Given the present findings, innovative breast cancer screening techniques should be 
initiated at a younger age (≤ age 40 years) for TNBC and African American women in 
particular, based on risk-benefit assessment studies. It is recommended that research on, 
and ushering in of, targeted biologic markers for both primary and secondary prevention 
of breast cancer subsets should be prioritized, as well as, the introduction of timely and 
more widespread histopathological typing for breast cancer subsets in institutions 
nationwide. The development of prophylactic agents for TNBC, analogous to the 
selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene for 
Luminal A and Luminal B subsets, is critically important for TNBC patients and similar 
subsets. As a result of the data presented here, there should be new impetus for research 
on the epidemiology and public health impact of TNBC and other breast cancer subsets.    
In summary, the main recommendation of this study is that greater public health 
attention and action for breast cancer and its subsets than is currently exhibited, needs to 
be introduced. Such an introduction, together with a range of supplementary actions, will 
significantly impact on the disproportionate survival rates of African American women. 
These supplementary actions should include changing public policy with regards to 
breast cancer prevention, diagnosis, treatment and quality of life for these patients; 
refocusing primary and secondary prevention strategies towards TNBC, other subsets and 
at-risk populations, specifically with regards to environmental, biological and 
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socioeconomic interventions and research efforts, focused on both treatment and public 
health interventions that are especially directed towards TNBC patients in general and 
African American women in particular as particular at-risk groups for this disease and its 
and prognostically unfavorable sequelae. 
ii. Conclusion 
 
African American race, younger age at diagnosis, uninsured status, higher grade at 
diagnosis, inadequate treatment are independent predictors of poor survival among breast 
cancer patients; importantly, TNBC had a lower survival than that of NTNBC patients. 
The survival disparity in African American women with breast cancer may partially be 
explained by disproportionately higher TNBC cases among them, as well as, higher rates 
of not receiving standard treatments.  
The main aim of this dissertation was to determine if there are variables that 
predict survival among TNBC and NTNBC patients and, if so, did disparities in survival 
exist for these same variables separately for TNBC and for NTNBC populations. The 
results showed that this aim was achieved; the research questions answered and affirmed; 
and the hypotheses supported by the data.   
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APPENDICES 
 
     APPENDIX A 
 
Cox Proportional Hazard Model 
The Cox proportional hazard model is a statistical or semi-parametric approach to 
survival analysis that uses marginal likelihood methods. It is a method that is used to 
evaluate the relationship between patient survival (or its inverse – hazard) and several 
other covariates. These covariates are also known as predictive or explanatory variables.  
The importance of these covariates can be assessed by the hazard function. Moreover, the 
quantitative impact of these covariates on survival measures can be assessed by the 
model. The more familiar non-parametric log-rank or Kaplan-Meir method can evaluate 
survival for one variable at a time. The Cox proportional hazard model can be used to 
simultaneously evaluate the effects of several variables on survival, where survival is 
taken to mean the time between which a patient enters and then exits a study either 
through death or some other defined endpoint or event.  
The model can also provide an estimate of the effect of an intervention on 
survival after an adjustment for other covariates, while allowing for an estimate of risk of 
death for a patient in the light of their prognostic variables. The Cox model in this study 
is fitted to the available data in a regression equation for the hazard function involving 
the chosen covariates of age, race, marital status, etc. The coefficients of these covariates 
(β) describes the model fit, such that a positive and large regression coefficient means 
that the hazard is higher and the prognosis worst, while a negative regression coefficient 
implies that the hazard is lower and the prognosis better for patients with higher 
magnitude of the associated covariates. 
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Censoring: When the period of observation is cut off before the event of interest occurs 
(still alive or lost to follow up, say) the subject is considered censored. If the subject’s 
survival time is greater than the duration of study observation, the subject is also 
considered censored. 
Interpretation of Hazard Function 
A hazard function h(t) is a ratio of counts per unit time, a “probability rate” that a subject 
will die within a finite period of time, such that the subject has survived at least up to the 
start of the interval duration; it is often considered the risk of dying at time t. (Note h(t) is 
a rate or a ratio of the number of subjects dying (counts) at the beginning of interval t 
over the product of the number of subjects surviving at time t (n(t)) and interval duration, 
D), such that: h(t) = f(t)/S(t), where S(t) = n(t).(D).  
h(t) = h0(t)e(βх) where h0(t) is the baseline hazard. 
In general: 
hi(t) = h0(t) * e(β1xi1+ β2xi2+...+ βkxik)  
The hazard function therefore describes the relative likelihood of the event occurring at 
time t, conditional on the subject surviving up to that time. It is counts per unit time (units 
time-1). The relationship between the presence or absence of death/event and the 
covariate could be assessed with logistic regression at a particular time by hazard ratio, h:  
h = e(β1xi1+ β2xi2+...+ βkxik)  
To statistically compare the difference between two survival curves requires survival 
analysis and use of hazard ratio (ratio of two functions). Note: the ratio eliminates the 
baseline hazard h0. Here, the β coefficient is considered a hazard risk or a risk of death 
(e.g. x-times greater risk of dying). 
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The Kaplan-Meir plot is step wise because the estimated survival probabilities are 
constant (horizontal) between adjacent deaths times and then decreases after each and 
every death (vertical line). The Cox cumulative probabilities is more continuous and 
instantaneous. 
The SPSS output shows a table in which B is the value of the coefficients, β. A 
positive coefficient indicates that the hazard increased and survival decreased. In that 
situation the hazard rate is increased in proportion for each unit of the reference variable. 
If negative the hazard is less than the reference.  
Example: For breast cancer subtype status, where TNBC is being compared with 
NTNBC or reference group, B is 0.826, hazard ratio 2.285, 95% CI (2.144, 2.434, p < 
0.0001) indicates that the estimated hazard or risk of death for a TNBC patient increases 
2.285 times that of a NTNBC patient. It indicates that there is an 83% increase in the risk 
of death after adjustment for the effects of the other variables in the model, which is a 
statistically significant difference in survival. 
The value of the Wald statistic is indicative of the importance of the variable for 
the model. The greater the Wald value, the greater the importance of the variable to the 
model. The Wald statistic is calculated for the variables in the model to help in the 
selection of the variables for removal from the model. Exponent of B [Exp(B] provides 
the exponential value of the beta coefficient, which is the Hazard ratio.  
Definitions in the Cox Model 
P-value: The probability of the data or more extreme data occurring by chance when the 
null hypothesis is true. 
Standard Error: A measure of the uncertainty or variability of the data or its spread. 
117 
 
Confidence Interval (CI): If the estimation is repeated many times, then 95% of the 
estimated intervals will contain the true value within the interval. 
Principal Information Source  
Walters SJ. What is a Cox Model? Hayward Group. 2009. 
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APPENDIX B 
 
Raw Computer Data 
 
Table B 1: Survival data for NTNBC versus other variables 
 
 
 B SE Wald df Sig. OR 
95.0% CI for 
Exp(B) 
Lower Upper 
GRADE I   560.396 3 .000 Ref.   
GRADE II .298 .045 44.174 1 .000 1.347 1.234 1.470 
GRADE III .922 .045 412.424 1 .000 2.515 2.301 2.749 
GRADE IV 1.030 .176 34.230 1 .000 2.802 1.984 3.957 
80 years and 
above   16.110 5 .007 Ref.   
< 40 years -.122 .242 .253 1 .615 .886 .552 1.422 
40-49 years -.343 .185 3.451 1 .063 .710 .494 1.019 
50-59 years -.300 .142 4.486 1 .034 .741 .561 .978 
60-69 years -.248 .101 5.982 1 .014 .780 .639 .952 
70-79 years -.133 .064 4.279 1 .039 .875 .771 .993 
Surgery 
performed      Ref.    
No-Surgery 2.135 .034 3952.924 1 .000 8.458 7.913 9.040 
Radiation given      ref   
No-Radiation .578 .037 242.159 1 .000 1.783 1.658 1.918 
Age at 
Diagnosis .032 .004 56.748 1 .000 1.033 1.024 1.041 
Non-Hispanic      Ref.   
Hispanic -.053 .056 .897 1 .344 .949 .850 1.058 
White   47.395 2 .000 Ref.   
Black .224 .045 24.659 1 .000 1.251 1.145 1.367 
Other -.284 .067 17.679 1 .000 .753 .660 .859 
Insurance      Ref.   
No Insurance .486 .096 25.498 1 .000 1.627 1.347 1.965 
Married      Ref.   
Unmarried .365 .034 116.175 1 .000 1.440 1.347 1.538 
a. Triple Negative = Non-Triple Negative 
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Table B 2: Survival data for TNBC versus other variables 
 
 
 B SE Wald df Sig. OR 
95.0% CI for Exp(B) 
Lower Upper 
GRADE I   29.544 3 .000 Ref.   
GRADE II .681 .233 8.577 1 .003 1.976 1.253 3.116 
GRADE III .926 .226 16.773 1 .000 2.524 1.621 3.932 
GRADE IV 1.147 .297 14.885 1 .000 3.148 1.758 5.637 
80 years and 
above   51.467 5 .000 Ref.   
< 40 years .392 .407 .931 1 .335 1.480 .667 3.284 
40-49 years .095 .322 .087 1 .769 1.099 .585 2.067 
50-59 years -.171 .249 .470 1 .493 .843 .517 1.374 
60-69 years -.313 .180 3.028 1 .082 .731 .514 1.040 
70-79 years -.281 .118 5.645 1 .018 .755 .599 .952 
Surgery 
performed      Ref.   
No-Surgery 2.198 .059 1408.631 1 .000 9.008 8.032 10.104 
Radiation given      Ref.   
No-Radiation .274 .055 24.378 1 .000 1.315 1.180 1.466 
Age at Dx .032 .008 17.274 1 .000 1.033 1.017 1.049 
Non-Hispanic      Ref.   
Hispanic -.096 .087 1.209 1 .272 .909 .766 1.078 
White   13.752 2 .001 Ref.   
Black .109 .062 3.046 1 .081 1.115 .987 1.260 
Other -.348 .117 8.906 1 .003 .706 .562 .887 
Insurance      Ref.   
No Insurance .618 .123 25.180 1 .000 1.854 1.457 2.360 
Married      Ref.   
Unmarried .345 .054 40.594 1 .000 1.413 1.270 1.571 
a. Triple Negative = Triple Negative 
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